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Abstract 
Chronic kidney disease (CICD) is a significant public health issue that affects an 
estimated 11 percent of adults over the age of 25 years in Australia. Slowing the 
progression of kidney disease is a major therapeutic challenge for nephrologists. 
Oxidative stress is an imbalance between reactive oxygen species (ROS) and 
antioxidants levels in cells or tissues. It has been linked to a number of diseases, 
including cardiovascular disease (CVD) and CICD. Decreased antioxidant levels can be 
caused by a number of factors, such as, genetic mutations that reduce the effectiveness 
of the antioxidants, or toxins that deplete the concentration of antioxidant enzymes. 
Antioxidants may be separated into two distinct groups, exogenous and endogenous 
compounds. Important endogenous antioxidant enzymes include superoxide dismutase 
(SOD), glutathione peroxidase (GPx) and catalase which together form the primary 
defence system against ROS. 
In recent years, the relationship between single nucleotide polymorphisms (SNPs) of 
antioxidant enzymes and diseases associated with oxidative stress has been a topic of 
significant interest. SNPs of the antioxidant enzymes SOD2 Alal6Val, GPx1 
Pro197Leu and catalase C-262T have been associated with the pathogenesis of cancer, 
cardiovascular disease and diabetes. However, links between SNPs of these enzymes 
and CICD have yet to be investigated. Thus, the overall aim of the present study was to 
determine associations between antioxidant enzyme SNPs, antioxidant activities and 
renal function at baseline and changes thereof over a year in CICD patients. 
Two major studies will be presented. The first uses a case-control design and baseline 
data from the CICD patient cohort (n=230) and control subjects (n=224) to determine (a) 
the frequency of specific SNPs, present in GPx, SOD and catalase genes and whether 
xi 
antioxidant enzyme activities are significantly different between CIO patients (n=230) 
and control subjects (n=224), and (b) associations between antioxidant genotypes and 
renal function. The second study uses baseline and one year data from 185 CKD 
patients from the cohort and investigated whether the progression of kidney disease (i.e, 
decline in eGFR) was (a) associated with specific genotypes resulting from the 
aforementioned GPx, SOD and/or catalase SNPs, and (b) associated with altered plasma 
GPx, RBC GPx, RBC SOD and/or RBC catalase activities. 
In the case-control analysis, significantly (p=0.023) more CKD patients had the GPx 
Leu/Leu genotype (n=5) compared to controls (n=0). Although not statistically 
significant, patients with the GPx1 Leu/Leu or SOD2 Ala/Ala genotypes had reduced 
eGFR compared with the GPx1 Pro/Leu and SOD2 ValNal genotypes. CKD patients 
had significantly lower plasma GPx and RBC catalase activities compared to controls 
(p<0.0001). In contrast, both RBC GPx and RBC SOD activities were significantly 
higher in CKD patients (p<0.0001). In addition, in CKD patients, a significant positive 
association was found between eGFR and plasma GPx activity (p<0.0001). Plasma GPx 
increased (p<0.0001) and RBC GPx decrease (p<0.05) with disease progression from 
Stages 1 to 5. Interestingly, when the controls were stratified according to eGFR (and 
hence, Stage of CKD), 13% (30 subjects) were found to be in Stage 3 according to 
Kidney Disease Outcomes Initiative (KDOQI) guidelines. 
The second study showed that eGFR declined over 12 months in both SOD2 Ala/Vat 
and Val/Val patients, indicating a more rapid progression of kidney disease compared to 
patients with the Ala/Ala genotype (Ala/Val compared with Ala/Ala: p=0.001; VaVVal 
compared with Ala/Ala: p=0.005). The progression of CKD did not appear to be 
influenced by SNPs of GPx1 or catalase. There was a direct relationship between the 
rate in change of plasma GPx activity and the rate of change of eGFR over the 12 month 
period (p=0.025). 
xii 
In summary, this is one of the largest case-control studies comparing antioxidant 
enzyme genotypes and activities in CKD patients conducted to date. In addition, this 
study is the first (cohort) study to investigate the role of antioxidant enzyme SNPs in the 
progression of CKD. The data suggest that CKD is associated with impaired plasma 
GPx and catalase activities and enhanced RBC GPx and SOD activities when compared 
to controls. Secondly, although genotype frequencies were similar for patients and 
controls, lower eGFR was associated with the GPx1 Leu/Leu genotype. Thirdly, CICD 
patients with the SOD2 Ala/Val or Val/Val genotype had a greater decline in kidney 
function over the 12 month study period when compared to patients with SOD2 Ala/Ala 
genotype. These findings suggest that SOD and GPx therapies that enhance the 
activities of these antioxidants may slow the progression of CICD. In addition, as 13% 
of the control participants were found to have impaired kidney function (eGFR 
<60mL/min/1.73m2), there appears to be significant undiagnosed CKD in Northern 
Tasmania, that may warrant routine assessment of kidney function in the general 
population. 
CHAPTER 1: GENERAL INTRODUCTION 
1.1 Chronic Kidney Disease (CKD) 
CKD is a debilitating and potentially fatal disease which affects an estimated one in 
seven of adults over the age of 25 years in Australia.' In 2008, there were 10,062 
individuals receiving dialysis treatment in Australia with 2,476 newly diagnosed. Of 
these, 177 were recorded in Tasmania and 52 were recently diagnosed. 2 Treatment for 
end stage renal disease (ESRD) costs approximately $80,000 per patient per year. 3 
However, the combined economic, social and personal cost is impossible to measure. 
To date, 177 Tasmanians have received kidney transplants with the follow-up care 
increasing the financial burden.2 There is considerable social and personal cost involved 
which varies between patients due to their response to treatment and level of supportive 
care required for everyday activities. Therefore, tests that can identify individuals who 
may have a faster progression of CKD, may help with slowing the progression of this 
potentially fatal disease. 
1.1.1 Stages 
Renal function is monitored by measuring estimated glomerular filtration rate (eGFR). 
The clinical definition of CKD is eGFR of less than 60mL/min/1.73m 2 body surface 
area for longer than three months or demonstrable kidney damage. 4, 5 To aid in the 
development of specific treatment plans for each patient and to evaluate the disease 
progression, CKD has been classified by Kidney Health Australia into 5 different 
stages.6 The scale starts at the early stages of CKD, which require no medical treatment, 
to renal failure, which requires either dialysis or kidney transplant for the survival of the 
patient (Table 1-1). 
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Table 1-1: Stages of Chronic Kidney Disease 
Stages 	 Description 	 eGFR 
(mlimin/1.73m 2 ) 
1 	Kidney damage with normal/increased GFR. 
If the eGFR is >60mL/min/1.73m 2 for more 
than 3 months or more then this is classed as 
CICD.Defined when there has been kidney 
damage for more than 3 months, then this is 
classified as CICD. This will be determined > 90 
by kidney biopsy or the presence of markers 
such as albumin/creatinine ratio or total 
protein/creatinine ratio which indicate kidney 
damage. 
2 	Kidney damage with small reduction in 
eGFR and classified as mild CICD. 	 60-89 
3 	This measurement of the eGFR has to have 
occurred for 3 months or more (with/without 
the kidney damage markers), classified as 
moderate CICD. 
4 	This measurement of the eGFR has to have 
occurred for 3 months or more (with/without 
the kidney damage markers), classified as 
severe CICD. 
5 	ESRD. The patient should be considered for 
renal replacement therapy, i.e. transplant or 
dialysis. 
30-59 
15-29 
<15 
Table Modified from Kidney Health Australia6 
1.1.2 Progression / Monitoring 
Monitoring the progression of renal disease is important for ensuring the efficacy of the 
treatment and also estimating the time until ESRD. The rate at which CICD progresses 
varies considerably and this makes it difficult to accurately determine the rate at which a 
patient's kidney function will deteriorate. In addition, it has been well documented and 
reviewed that the progression of kidney function is associated with the ageing process 
due to number of factors including the reduction in renal mass and changes in 
glomerular structure. 7 Diagnostic tests used to monitor the progression of CKD include 
creatinine clearance, serum creatinine concentration and plasma urea 5 8 . Creatinine 
clearance is calculated using urine creatinine concentration (gmol/L) (measured from 24 
2 
hour urine samples), urine flow rate (mL/min)5 ' 8 and the, serum creatinine concentration 
(gmol/L) to give an estimate of true glomerular filtration rate (GFR) (healthy adults 
have a GFR of —120mL/min). 5 
Serum creatinine concentration is a convenient way to estimate glomerular filtration 
(i.e., eGFR). There are two different ways by which this can be determined the 
Cockcroft-Gault, and Modification of Diet in Renal Disease (MDRD) equations. Both 
formulae use the age and gender of the patients. However, in the Cockcroft-Gault 
equation, the patient's weight is used as a regulator within the calculation, whereas the 
MDRD uses ethnicity within the equation.4 ' 5 Serum creatinine concentration depends 
on muscle bulk and can change independently of renal function due to an increase or 
decrease in the patients' muscle mass. Therefore, due to variations in body composition 
with age, an athletic young man may have a similar serum creatinine concentration to an 
elderly woman with a renal problem. The reference range for an adult is 60-120gmol/L, 
although an individual's results will not vary by that proportion on a daily basis. There 
may be some discrepancies when measuring eGFR in the early stages of renal disease, 
as small increases in serum creatinine may result in major discrepancies in eGFR. There 
is also a problem when measuring eGFR in patients in the advanced stages of CICD, 
where small changes in eGFR do not reflect the large changes in serum creatinine. 9 
MDRD was considered the standard calculation for determining eGFR in 2005, when 
this study was designed and still forms the basis for the current NICF KDOQI CICD 
classification. However, currently there is controversy regarding the use a new and 
maybe more accurate method of calculating eGFR, the Chronic Kidney Disease 
Epidemiology Collaboration (CICD-Epi), hence in future studies this measurement 
maybe replace MDRD. 
It is important for the nephrologist to monitor the decline in renal function regularly, as 
this can help determine the effect that treatment is having on the kidney function as well 
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as help with estimating the time at which the patient will require dialysis or renal 
replacement. 
1.1.3 Causes 
There are a number of underlying causes of CKD. Some of these causes are outlined in 
Table 1-2. 
Table 1-2: Causes of Chronic Kidney Disease 
Cause of Disorder 	Examples 
Immunologic 
Infection 
Urinary Obstruction 
Metabolic 
Vascular 
Hereditary Kidney Diseases 
Nephrotoxin-induced 
Other 
Glomerulonephritis 
Pyelonephritis, tuberculosis 
Neoplasm, urethral constriction 
Diabetes mellitus, gout, amyloidosis 
Hypertension, infarction, sickle cell anaemia 
Polycystic Kidney disease, Butter's syndrome, 
Alports syndrome, renal hypoplasia 
Analgesic nephropathy, drugs, heavy metal 
poisoning, industrial solvents, radiation nephritis 
Multiple myeloma, hypocalcaemia 
Table modified from Patho Physiology 12 
1.1.4 Incidences in Australia 
In 2008, for the fifth consecutive year, diabetic nephropathy (34%), including type 1 
diabetes mellitus (T1DM) and type 2 diabetes mellitus (12DM), was the main of cause 
of ESRD in Australia. Diabetes surpassed glomerulonephritis as the main cause of 
ESRD due to the increased numbers of individuals with T2DM, that make up 91% of 
diabetic nephropathy patients in Australia, who progressed to ESRD.2 
Glomerulonephritis, or inflammation of the glomeruli in the kidney, was the next major 
cause of ESRD in 2008 (22%). In addition, hypertension or vascular disease, contributes 
to 15% of CKD cases; reflux nephropathy, 3%; polycystic kidney disease, 6%; and 
analgesic nephropathy, 2%. These six are the main causes of CKD and the rest fall 
under the title of miscellaneous causes, which accounts for approximately 10% of CKD 
cases.2 In Australia in 1998, there were 296 per million of the population receiving 
dialysis, and this increased in 2008 to 471 per million population. 2 The detection of 
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CKD is difficult in the early stages due to the lack of symptoms. However, in the later 
stages, uraemic syndrome is the main symptom of extreme renal failure, resulting from 
the increase in waste products (e.g., urea) in the blood and the reduced removal of 
nitrogen from the blood stream. 13 The symptoms of uraemic syndrome are discussed in 
more detail in section 1.1.5. 
1.1.5 Symptoms 
Most symptoms are identified under the heading of uraemic syndrome, resulting in 
systemic renal failure that affects all the body systems 12 (Table 1-3). The neurological 
system is affected by an increase in neurotoxins (mainly in the later stages of CK13), 
deficiency of ionized calcium in the spinal cord, retention of potassium and phosphates 
and altered fluid balance. 12 ' 14 As specific pathways gradually deteriorate, a number of 
symptoms occur ranging from drowsiness, an inability to concentrate and poor memory, 
to more severe symptoms including hallucinations and seizures that may eventually lead 
to coma. 14 When the gastrointestinal system is affected, the patient can have nausea, 
vomiting and/or anorexia. However, it is speculated that it could be due to the gastric 
ulcers that occur in a high percentage of CKD patients. 12, 121 Gastric bleeding also 
affects the haematologic system by causing anaemia. Anaemia can be caused by a 
number of other factors including the shortened life span of red blood corpuscles (RBC) 
and a decrease in erythropoietin (due to the reduction in renal production and 
secretion), I5' 16 Anaemia also occurs due to a deficiency in folate, iron and an increased 
production of parathyroid hormone. Parathyroid hormone leads to fibrous tissues taken 
up bone marrow space, which affects the overall musculoskeletal system. 12 In addition, 
the musculoskeletal system is affected by a calcium imbalance which results from a 
reduction in the bones' ability to absorb calcium, a condition known as osteodystrophy. 
This imbalance can also cause a number of bone lesion conditions. I2 However, the 
major effect of uraemic syndrome is on the cardiovascular system, with fifty percent of 
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CKD patients dying prematurely from cardiovascular complications. 17-19 The reasons 
for the deterioration in cardiovascular function are vascular changes and increased 
secretion of renin which leads to hypertension, pericarditis and narrowing of arteries. 
With numerous studies reporting links between CVD, inflammation and oxidative 
stress, this study focuses specifically on oxidative stress in CKD patients. Although, 
inflammation may play an important role in the oxidative stress along with progression 
of CKD, however this is beyond the scope of this thesis." 
Table 1-3: Clinical Features of Chronic Kidney Disease 
Clinical Features 	Description of symptoms 
Cardiovascular 
Gastrointestinal 
Muscular and skeletal 
Neu ropath 
Well being 
Dermatological 
Hematologic 
Hypertension, anaemia and pericarditis 
Anorexia, nausea, vomiting and gastrointestinal bleeding 
Disorders of calcium and phosphorus, bone pain, 
myopathy and growth failure 
Lethargy, peripheral neuropathy 
Depression 
Pruritus, pallor, ecchymoses and hyperpigmentation 
Anaemia 
Table modified from Patho Physiologyn 
1.2 Interactions between Reactive Oxygen Species and 
Antioxidants 
1.2.1 Oxidative Stress and Antioxidants 
The term oxidative stress is used to describe a relative increase in the amount of reactive 
oxygen species (ROS) and includes not only oxygen radicals but also non-radical 
derivatives such as, nitrogen and chlorine. 21 Oxygen free radicals and hydrogen 
peroxide (H202) are produced and reused during normal metabolism by cells. The ROS 
have an unpaired electron giving them the capability to cause damage by reacting with 
lipids, proteins and deoxyribonucleic acid (DNA). 19 Oxidative stress is an imbalance 
between antioxidants and oxidants. The progression of many diseases has been linked to 
oxidative stress, including CVD, 22 cancers,23 diabetes,24 CKD,25 Alzheimer's disease 
and other neurodegenerative diseases. 26 ROS are unstable and cause damage to 
macromolecules via oxidation. Oxidative stress can occur due to an increased 
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concentration of reactive species and/or a reduction in antioxidant capacity. This can be 
caused by a number of factors such as a genetic mutation that alters the effectiveness of 
the antioxidants," toxins that diminish the antioxidant enzyme28 or disease processes 
that can deplete the concentration of antioxidants.29 Antioxidants are the body's defence 
against ROS and may be exogenous or endogenous compounds. Exogenous 
antioxidants are consumed in the diet and consist largely of carotenoids (e.g. 13- 
carotene), tocopherols (e.g. vitamin E), ascorbic acid (vitamin C) and selenium. 
Endogenous antioxidants include thiols such as glutathione and the enzymes superoxide 
dismutase (SOD), glutathione peroxidase (GPx) and catalase. These antioxidant 
enzymes are an important defence against ROS and work together by scavenging ROS 
and thereby reducing oxidative stress. 
1.2.2 Superoxide Dismutase (SOD) 
SOD contains an active site that has transition metals for rapid electron exchange. The 
major role of SOD is to scavenge the free radical, superoxide (02.) and convert it to 
H202 (Figure I-1). 30 Although there are many factors that affect the activity of these 
antioxidants, it has been reported that high levels of 11202 inhibit SOD and activate 
catalase.3I Three isoforms of SOD have been identified. SOD! contains copper (Cu) and 
zinc (Zn) within the active site (also known as CuZn SOD), and is mainly found in the 
cytoplasm of cells. The second isoform is SOD2 or manganese (Mn) SOD which 
contains manganese in the active site. SOD2 is the only antioxidant enzyme known to 
be present within mitochondria. This has important implications due to mitochondria 
being a major site for the production of ROS during normal cellular metabolism. 32 
SOD3, or extracellular (EC) SOD, also has Cu and Zn within the active site and is the 
least studied of the three SOD isoforms. 33 
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1.2.3 Glutathione peroxidase (GPx) 
GPx is a selenioprotein, which is responsible for the breakdown of H202 and other 
organic peroxides, including oxidised membrane phospholipids, as well as cholesterol 
and long chain fatty acids (Figure 1-1). GPx metabolises these substances and converts 
them to water and oxidised glutathione (GSSG) using glutathione as a reducing agent. 34 
In the structure of GPx, there is a single seleno-cysteine residue present in the active site 
which is essential for the activity of GPx and is present in all five isoforms of the 
enzyme that have been identified to date. 38-37 GPx1 (cGPx; RBC GPx) is found in 
cytoplasm and red blood cells (RBC). It is synthesised in the kidney and also produced 
in smaller amounts by the liver. 38 GPx2 is a cytosolic form found in liver and colon, 
whereas GPx3 (plasma GPx) is the only extracellular form of the GPx family that is 
found in plasma. GPx3 is primarily produced within the proximal tubule cells in the 
kidney where decreased activity correlates with a decrease in renal function. 3941 GPx4 
(PHGPx) is a phospholipid hydroperoxide and a monomer in structure, whereas the 
structure of the other GPx's are tetramers. GPx4 is found in most tissues, although it has 
been found in high levels in the testis and is a structural protein in the heads of sperm. 42 
Finally, there are few details on GPx5 available: 43' " It has been thought that GPx is the 
main antioxidant enzyme involved in the breakdown of H202. However, more recent 
studies suggest that GPx and catalase activity share this role equally. 45,46 
1.2.4 Catalase 
Catalase is a tetrameric haemoprotein that converts H202 to H20 and 02 (Figure 1-1). 
The reaction requires two H202 molecules; therefore it has a high conversion rate. 47 
Catalase is present in all aerobic cells, with the highest levels in the liver, kidney and 
erythrocytes. Acatalasaemia is an inherited autosomal recessive disease caused by an 
abnormality of the catalase gene. This disease is characterised by severely reduced 
catalase activity within erythrocytes and the main clinical symptom is persistent oral 
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gangrene." In addition, it has been proposed that impaired catalase activity has a direct 
relationship to the oxidant sensitivity of glucose-6-phosphate dehydrogenase (G6PD)- 
deficiency and impaired catalase activity. G6PD maintains levels of glutathione, which 
is intimately involved in the conversion of 11202 to water and oxygen by GPx." 
1.2.5 Pathways for Reactive Oxygen Species and Antioxidants 
A number of biochemical reactions produce 02*, a very reactive substance due to the 
extra outer shell electron. In crossing biological membranes, it can either promote free 
radical signals or induce oxidative damage. Antioxidants protect cells and tissues from 
damage by ROS and are able to recycle the ROS present in the cell or tissue (Figure 
1-1).50' 51 SOD is responsible for the conversion of superoxide to 11202 through a 
catalytic reaction. However, superoxide may also react with nitric oxide (NO), a 
vasodilator released by endothelial cells, producing peroxynitrite (ON00*), which is 
also a very reactive and permeable oxidant. I1202 can react or interact with a number of 
chemicals and follow several different pathways. One of these pathways involves the 
interaction of H202 with iron or copper to produce the hydroxyl radical (*OH) — another 
ROS. However, when an imbalance occurs, due to either a decrease in the antioxidants 
(e.g., SOD, GPx or catalase) or an increase in ROS levels, the cell succumbs to 
oxidative stress. A reduction in either enzyme function or over-production of ROS can 
lead to oxidative stress, and this has been linked to the progression of kidney disease. 13 ' 
44, 52-54 
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Figure 1-1: Simplified pathways of reactive species and the major antioxidants that defend cells and 
tissue from damage. 
Diagram modified from Morena et al. and Tylicki et al. 50 ' 51 
Superoxide (0 2 .); oxygen (0 2); superoxide dismutase (SOD); glutathione peroxidase (GPx); hydrogen 
peroxide (H202 ); peroxynitrite (0N00 .); nitric oxide (NO); hydroxyl radicals ( .0H); iron (Fe 2*); copper 
(Cu*); hydrogen (H 20); oxidised glutathione (GSSG); glutathione (GSH). 
1.2.6 Markers of Oxidative Stress 
CKD patients are monitored for an increased risk of developing CVD and this is 
normally predicted by the Framingham risk factors. 55 However, in more recent times 
there has been an increased use of less traditional methods of measuring the risk of 
CVD, viz, the measurement of specific chemical biomarkers present in the body that 
signal the increase in oxidative stress and/or inflammation."' 19 ' 44 ' 54 The biomarkers 
that are currently used to indicate oxidative stress and inflammation in humans are listed 
in Table 1-4. 
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Table 1-4: Common Biomarkers for Oxidative Stress and Inflammation 
BioMarkers Marker for References 
   
Lipid Oxidation 
LOOH 
LDL 
TBA 
TBARS 
Arachidonic Acid 
Derivatives 
F2-isoprostanes 
Carbohydrate 
AGE 
Amino Acids 
Cysteine 
Homocystiene 
Cytokines 
(IL)-6 
TNF-a 
Proteins 
CRP 
Thiol oxidation 
Carbonyl formation 
AOPP 
Oxidative 
stress 
Oxidative 
stress 
Inflammation 
Oxidative 
stress 
Inflammation 
Inflammation 
Oxidative 
stress 
Oxidative 
stress 
17, 44, 54, 56-59 
17,25,54,58 
17,58 
17,18,25,54 
17,56,57,60 
17,18,25,54 
17,18,25,54,57,60 
17,25 
17,18,58 
Deoxyribonucleic acid 	Oxidative 
	58 
8-0HdG 	 stress 
LOOH, lipid hydroperoxide; LDL, low-density lipids; TBA, thiobarbituric acid; TBARS, 
thiobarbituric acid reactive substance; AGE, advanced glycosylation end products; (IL)-6, 
interleukin; CRP, C-reactive protein; AOPP, advanced oxidation protein products; 8- 
OHdG, 8 hydroxy 2' deoxyguanine. Table modified from Himmelafarb." 
High-density lipoprotein (HDL) is involved in reducing oxidized low density lipids 
(LDL). As renal function decreases, so does the concentration of HDL, and an increase 
in oxidized LDL will occur due to oxidative stress." It has been noted that lipid 
peroxidation is increased in haemodialysis (HD) and ESRD (creatinine 666 ± 
91pmoUL) patients compared with healthy controls, thus demonstrating that both HD 
and ESRD patients are subject to oxidative stress. I9 Thiobarbituric acid reactive 
substances (TBARS) are another measure of oxidative stress. TBARS measure 
aldehydes, such as malondialdehyde (MDA). However, this test is not very specific and 
can be quite inaccurate.58 F2-isoprostanes are markers for oxidative stress and measure 
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the levels of free radicals produced by oxidation of arachidonic acid. Free F2- 
• isoprostanes have been shown to increase in CKD patients. 25  This btomarker test is 
relatively new and has been found to be more reliable for determining levels of 
oxidative stress, although it is a more complex test that requires expensive equipment. 58 
Inflammatory cytokines and proteins such as C-reactive protein (CRP) and fibrinogen 
are also believed to be good markers. 18 The levels of CRP have been found to predict 
mortality in HD patients. 57 It has also been shown to be associated with the 
development of CVD complications in CKD patients. 18 
Oxidative proteins, such as advanced oxidation protein products (AOPP), are more 
stable markers than lipids. The increase in AOPP in CKD patients has been associated 
with an increased risk of developing CVD complications. 18 However, it has been 
demonstrated that an increase in triglyceride levels in both CKD patients and healthy 
controls can increase the measurement of AOPP. 61 Another protein marker for oxidative 
stress is carbonyl formation which indicates the amount of reactive aldehyde in 
plasma.25 Oxidative stress has also been linked to damaged DNA, by mutated bases or 
breaks on strands caused by ROS for which the biomarker is 8 hydroxy 2' 
deoxyguanine (8-0HdG).58 Other factors that have been found to be associated with 
CVD and are related to oxidative stress are malnutrition and endothelial dysfunction. I2 
Endothelial cell dysfunction has been shown to be important in the early stages of 
cardiovascular complications. 59 Although the antioxidant enzymes, GPx, SOD and 
catalase, have been suggested as markers for oxidative stress, there have been 
conflicting data published in relation to CKD. However, only plasma GPx has shown 
potential as a marker of oxidative stress in CKD patients. I3 ' 35 ' 53 ' 62-67 
1.2.7 Antioxidant Single Nucleotide Polymorphisms (SNPs) 
In recent years, there has been increased interest in the relationship between mutations 
of the genes encoding antioxidant enzymes and the diseases associated with oxidative 
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stress. The most common mutation studied has been the SNP which occurs when single 
bases are changed or deleted. This mutation may result in a change in amino acid and 
hence, a change in phenotype. During the course of the present study, a number of large 
population studies emerged in the literature that aimed to expand the database of SNPs 
and haplotypes present in the human genome. The International HapMap Project 68, is a 
recent database set up to develop a haplotype map, to be used for identify common 
genetic variations in of the human genome. In addition, the Human Variome 
Project69and 1000 Genomes Project" were also both set up to help in the determining 
the effect of genetic variation on human health. The SOD, GPx and catalase SNPs 
selected for this study constitute the majority of the published research on antioxidant 
SNPs. The SOD2 rs4880 Alal6Val SNP is a substitution of alanine (Ala) to valine (Val) 
at amino acid position 16. The GPx1 rs1050450 Pro197Leu SNP, a substitution of 
proline (Pro) to leucine (Leu) at amino acid position 197. Catalase rs1001179 C-262T 
SNP (C: base cytosine; G: base guanine) have not been examined to the same extent as 
the 50D2 SNP, although both appear to have significant associations with disease. An 
extensive review of the literature regarding these three SNPs and disease will be 
covered in section 2.3. The aforementioned SNPs are reported to be associated with 
altered progression and/or risk of several diseases, including CVD, 71.73 breast cancer,74 
lung cancer, 75 diabetic neuropathy76 and acute renal failure. 77 Based on recent literature, 
there is potentially a link between diseases associated with oxidative stress, antioxidant 
genotypes and activities. However, these SNPs have yet to be investigated in relation to 
- C1(13. Therefore, a primary aim of this thesis is to determine if there is an association 
between CKD and the antioxidant gene SNPs, 50D2 Alal6Val, GPicl Pro197Leu and 
catalase C-262T. 
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CHAPTER 2: LITERATURE REVIEW 
2.1 Relationship Between Oxidative Stress and CKEI 
Oxidative stress has been shown to be particularly prevalent in CKD patients. 19 . 25 ' 56' 59' 
78 ' 79 As early as 1994, 19 it was shown that there was a correlation between HD and 
oxidative stress. Increased lipid peroxidation has been linked with the increase in 
mortality of HD patients. 57 Oberg, McMenamin-Crow et al. 8° concluded that even 
before renal replacement is required, patients with CKD at stages 3-5 show signs of 
oxidative stress. 25 Antioxidant activities (SOD, GPx and catalase) have been used as 
markers in HD and CKD at stage 4 and 5 patients. 19 ' 59 ' 79' 81 Other studies have shown 
that when a patient receives a kidney transplant, there is a notable decrease in the levels 
of oxidative stress markers compared with patients on HD, and antioxidant levels in 
transplant recipients may return to normal levels when they have normal renal 
clearance. 78 Oxidative stress in CKD patients has been linked to endothelial-dysfunction 
which has also been associated with the increase in the mortality of CKD patients from 
premature CVD.59 In addition, endothelial-dysfunction has been reported to be present 
in all stages of CKD and has a strong correlation with the decline in eGFR. 82 Impaired 
endothelium-dependent vasodilation and oxidative stress is apparent in stage 5 CKD 
patients. In a study involving 37 patients with chronic renal failure that were thought to 
require renal replacement therapy in the near future, oxidised glutathione (GSSG) 
positively correlated with serum creatinine concentration. 59 ' 79 A study by Fumeron, et 
a1, 83 reported that in HD patients, GSSG and glutathione (GSH) increased during short 
term treatment with vitamin C supplements. However, GSSG and GSH returned to pre-
supplementation levels soon after treatment. 83 This shows that although GSSG and GSH 
are affected by the decrease in the kidney function, the addition of vitamin C 
supplementation short term, does not increase GSSG and GSH sufficiently to have a 
significant benefit on HD. 83 Finally, it has been shown that patients on HD with 
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increased iron storage also have DNA injury due to oxidative stress." In conclusion, 
there is some evidence that oxidative stress is prevalent in CKD and dialysis patients 
which may contribute to the progression of the disease and associated co-morbidities. 
2.2 Antioxidant Activities in Relation to CKD Disease 
The relationship between antioxidant enzymes and CKD has mainly revolved around 
glutathione peroxidase (GPx). Indeed, eight studies have examined GPx activity in RBC 
lysate or plasma in non-dialysis patients 13, 35, 53, 62-66 and of these, two also investigated 
SOD activity. 53 ' 63 However, there have been no studies that have examined the 
activities of all three antioxidants in CKD patients to date. 
Although, Zwolisska and co-workers85 examined RBC GPx, SOD and catalase activities 
in child/young adult (aged 5-18 years) dialysis patients (peritoneal dialysis (PD), 10; 
HD, 21), and found that both RBC GPx, RBC SOD and catalase enzyme activity were 
significantly reduced compared to healthy age matched controls. However, this result 
did not correlate with the patient's serum creatinine levels. 85 
Studies examining the relationship between GPx enzyme activity and CKD have 
resulted in conflicting reports, depending on whether activity was measured in plasma 
or RBC. Zachara et al. 62 examined 150 CKD patients at different stages of the disease 
and found CKD patients had decreased RBC GPx. However, there was no association 
with the antioxidant activity and stage of the disease. 62 In addition, three smaller studies 
all supporting this finding in CKD patients. Richard and co-workers examining 14 CKD 
patients with high blood creatinine levels (-442gmo1/1) found that RBC GPx was 
significantly reduced compared to a healthy control group. 65 Another study that 
involved renal patients at different stages of impairment, including 12 patients 
diagnosed with nephrotic syndrome, 48 CKD, 50 HD patients, and 50 healthy controls, 
also reported RBC GPx activity was significantly decreased in the nephrotic syndrome 
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group and CICD patients when compared with the control group. 35 Bulucu et al.64 also 
reported reduced RBC GPx activity compared with control populations. In addition, 
both studies reported that there was no correlation between RBC GPx activity and 
serum creatinine.35 ' 64 In contrast, Ceballos-picot et al. 53 conducted a large case-control 
study involving 185 non-dialysis CICD patients (divided into groups from mild to severe 
CICD, based on creatinine clearance), and found that RBC GPx activity was increased in 
CKD patients compared with 31 healthy controls. 53 Furthermore, this finding was 
supported by a smaller case-control study with 36 CICD patients compared to 13 
healthy controls.63 However, this study also reported that RBC GPx activity increased 
with the severity of CICD.63 
Plasma GPx activity has been reported to be significantly decreased compared to 
healthy subjects and the decline correlates with the decline in the kidney fimction. 13 ' 35 ' 
53,62,63,66 Ceballos-picot et al.53 reported that in 185 non-dialysis patients (with mild to 
advanced renal failure) and 48 patients receiving dialysis (HD and PD), plasma GPx 
activity declined gradually as the kidney disease progressed. In addition, dialysis 
patients had significantly decreased plasma GPx activity compared with the control 
group. In a smaller study of only 18 CICD patients and 78 dialysis patients (20 HD and 
58 PD), plasma GPx activity in CICD was lower than in 118 healthy controls and 
inversely related to serum creatinine. 66 Plasma GPx activity was also significantly 
reduced in the HID and PD patients compared to controls, and plasma GPx activity was 
significantly higher in HD patients compared with the PD patients. The lowest plasma 
activity was found in females that were receiving PD. However, within the control 
group, females had higher plasma GPx activity compared with male controls. 66 In 
addition, this study reported that RBC GPx activity in non-dialysis and dialysis patients 
was significantly higher than in controls. 66 
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El-far et al.35 reported CKD patients had significantly reduced plasma GPx activity 
compared with the control group. However, this was not the case in patients with 
nephrotic syndrome. In addition, in CKD patients, there was a correlation between 
plasma GPx activity and serum creatinine and blood urea nitrogen levels, whereas RBC 
GPx activity showed no correlation with these two parameters. Plasma GPx activity was 
significantly increased pre-dialysis compared with post-dialysis but when compared 
with the control group, both were significantly decreased. 35 Another large study that 
examined plasma GPx enzyme activity involved 150 patients between the ages of 18-80 
at different stages of CI(D. The patients were divided into four groups (incipient, 55; 
moderate, 40; advanced, 40 and ESRD, 15), with the controls consisting of 30 healthy 
subjects aged between 23-64. Plasma GPx activity was significantly different between 
CKD patients and healthy controls. This study also found that as kidney function 
declined that there was a corresponding decrease in plasma GPx activity and patients 
with ESRD had one third the plasma GPx activity of healthy controls. 62 
Two smaller studies also found plasma GPx activity was significantly reduced 
compared to controls. Bulucu et al. 64 examined 20 nephrotic syndrome patients and 
Richards et al.65 investigated two groups, 14 non-dialyzed uremic patients and 17 CKD 
patients. Schiavon et al. 13 investigated only plasma GPx enzyme activity in 130 
individuals at various stages of CKD and subdivided them into groups according to their 
diagnosis, and compared them with 20 controls. They found that the plasma GPx 
activity was significantly reduced in patients with ESRD, prerenal ureamia and Bartter's 
syndrome, and renal transplant recipients. It was also noted that when plasma GPx 
activity decreased, this coincided with the increase in serum creatinine. I3 In addition, it 
has been well documented that plasma GPx is primarily produced within the proximal 
tubules of the kidney. Hence, when kidney function declines, the production of plasma 
GPx is also reduced.39-4I 
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Finally, only two studies examined both GPx and RBC SOD activity in CKD patients. 
Ceballos-picot and co-workers53 found that RBC SOD activity in CICD patients was 
similar to that of the control population, whereas RBC SOD activity was significantly 
reduced in HD patients compared with controls. 53 In contrast, Mimic-Oka and co-
workers63 found that RBC SOD activity was significantly increased in 36 non-dialysis 
patients compared with 13 controls and 10 HD patients. However, they also reported 
that HD patients had a decreased RBC SOD activity compared to both the control group 
and the non-dialysis CKD patients.63 It should be noted that this study was small and the 
age range was limited to 21-56 years old. 
In conclusion, studies of RBC GPx and SOD activities in CKD patients have been 
contradictory and catalase activity has yet to be investigated. Moreover, plasma GPx 
activity, although extensively investigated, has not been examined in CICD patients over 
an extended time period. To resolve the previous contradictory reports, the present study 
used large CKD and control populations and studied a cohort of the CKD patients over 
a 12 month period. Furthermore, as the influence of antioxidant enzyme SNPs in CICD 
patients' aetiology was unknown, the antioxidant genotypes of all participants were 
determined. 
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2.3 Relationships Between SNPs of Antioxidant Enzymes 
and Disease 
2.3.1 Abstract 
The presence and progression of numerous diseases have been linked to deficiencies in 
antioxidant systems. The relationships between abnormal genotypes arising from 
specific antioxidant enzyme single nucleotide polymorphisms (SNPs) and diseases 
associated with elevated oxidative stress have been widely studied. The purpose of this 
review is to analyse evidence from these studies. The antioxidant enzyme SNPs selected 
for analysis in this review are based on those most frequently investigated in relation to 
diseases in humans: superoxide dismutase (SOD)2 Alal6Val (79 studies), glutathione 
peroxidise (GPx)1 Pro197Leu (20 studies) and catalase C-262T (18 studies). Although 
the majority of evidence supports associations between the SOD2 Alal 6Val SNP and 
diseases such as breast, prostate and lung cancer, diabetes and cardiovascular disease, 
the presence of the SOD2 Alal6Val SNP confers only a small, clinically insignificant 
reduction in the risk of these diseases. Other diseases such as bladder cancer, liver 
disease, nervous system pathologies and asthma have not been consistently related to 
SOD SNP genotypes. The GPx1 Pro197Leu and catalase C-262T SNP genotypes have 
been associated with breast cancer, but only in a small number of studies. Thus, 
currently available evidence suggests antioxidant enzyme SNP genotypes are not useful 
for screening for several specific diseases in humans. 
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2.3.2 Introduction 
The most common mutation in DNA studied has been the SNP. A SNP occurs when 
single bases in genes are changed or deleted, and may result in an amino acid change at 
a specific position and therefore may produce a change in phenotype. The purpose of 
this section is to review and analyse studies that have investigated the relationships 
between SNPs arising from GPx, SOD and catalase antioxidant enzyme and diseases 
associated with elevated oxidative stress. After a general discussion of their many 
polymorphisms, one specific SNP and resulting genotypes will be examined in more 
detail. The antioxidant SNPs selected for this review and the present study were based 
on those most frequently studied in relation to diseases in humans. Indeed, the SNPs 
chosen in this review constitute the majority of the research in this area, i.e., of the 90 
articles reporting on SOD SNPs and disease, 79 addressed the SOD2 Alal6Val SNP, 20 
of 27 GPx studies investigated GPx Pro197Leu, and 18 of 25 catalase articles centred 
on the C-262T SNP. The National Centre for Biotechnology Information (NCBI) 
database was used to identify antioxidant enzyme SNPs and the PubMed (Medline) 
database was searched to locate original studies that investigated the relationships 
between the genotypes involved with the SNP and disease. The searches were 
completed on 1st June 2009. 
2.3.3 Superoxide Dismutase (SOD) Isoforms and SNPs 
The various isoforms of SOD have been discussed in section 1.2.2., with 111 SNPs 
identified for SOD1, 190 for SOD2 and 100 for SOD3 (NCBI) (1st June 2009) (see 
Appendix A5.2. for a link to SOD SNPs). 
Two SNPs of SOD1 have been studied in relation to disease and referenced in the NCBI 
database. The rs7277748 SNP is present in exon 1, in the TATA box promoter region, 
and changes A>G. No association was found between this SNP and familial 
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amyotrophic lateral sclerosis. 86 The SNP, rs1788180, is present in intron 1 and changes 
C>T. This SNP was found to be associated with an increased risk of nephropathy in 
patients with T1DM. 82 
There have been nine SNPs reported for SOD2 that are present in exons and therefore 
change the amino acid, and may affect the enzyme produced. Only two of these SNPs 
have been investigated in relation to disease occurrence. The most investigated SOD 
SNP, rs4880, is present in exon 2 and substitutes a C>T at position 2734. This changes 
the amino acid from alanine (Ala) to valine (Val) at position 16 (SOD2 Alal6Val 
genotype, although it has been referred to as Ala-9 Vat due to the SNP being at position 
9-amino acid upstream of cleavage site).88 This SNP has been the most widely studied 
because the Val allele of this SNP results in reduced expression and production of an 
unstable mRNA, which affects the import of SOD2 into the mitochondrion. 89 Seventy-
nine studies have investigated the relationship between the Alal6Val mutation and 
disease (see later 2.3.4). Another SOD2 SNP that is located in an exon is rs5746136 that 
produces an A>G substitution, and has been associated with an increased risk of 
Alzheimer's disease.9° A recently described mutation in the promoter region changes 
C>T at position -102, and therefore does not code for amino acids. 91-93 This SNP is not 
yet referenced in the NCBI database but the resulting SNP genotype has been associated 
with a positive outcome in breast cancer patients receiving radiotherapy? 
Five SNPs have been identified in the 5' end in the SOD3 gene, none of which code for 
amino acid production, although all have been investigated in relation to disease. Two 
SNPs, rs8192288 and rs8192287, are both mutations that change G>T and both have 
been investigated in relation to lung function (in normal individuals) and found to be 
associated with reduced forced vital capacity. % One study compared six SNPs present 
in SOD3 in hypertensive subjects and normotensive controls and found no differences 
in genotype frequency. Of the six SNPs, only rs13306703 and rs2536512 were 
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significantly associated with the presence of essential hypertension." Two of the SNPs 
present in exon 2, rs1799895 and rs2536512, are A>G missense mutations. One of the 
other SNPs was present in intron 1, rs17881426, and substitutes A>T. The other three 
were identified in the 5' region: rs13306703, which is a C>T substitution; rs699474, 
which is an A>C/G substitution, and rs699473, which is also a C>T substitution. The 
latter mutation was found to have no association with the occurrence of brain tumours. 96 
2.3.4 SOD2 (MnSOD) Alal6Val and Disease 
There have been 79 studies investigating the relationship between the SOD2 Alal 6Val 
genotype and disease, approximately half of which reported a relationship (Table 2-1). 
Associations with breast cancer,97-108 bladder cancer, I09 Behcet's disease, I I° prostate 
cancer, 111-117 lung cancer, I18 ' 119 cardiovascular disease, 7I ' 72 acute myeloid leukaemia, 120 
cardiomyopathy,73 T1DM and T2DM, 121-126 hypersensitivity to , para-phenylene 
diamine, I27 sclerosis, I28 non-alcoholic steatohepatitis, I29 malignant pleural 
mesothelioma, 13° motor neuron disease, I31 brain ttunours, 96 and schizophrenia'' 133 
have been reported. 
No association between SOD2 Alal6Val genotypes and breast cancer, I"' 134-136 bladder 
cancer, 112, 137 chronic obstructive pulmonary disease, 138-140 ovarian cancer, I41 skin 
cancer, 142 oesophageal cancer, 143-145 gastric cancer,93 pancreatic cancer, I46 asthma,I47. 148 
non-Hodgkin lymphoma, 149, 150 lung cancer,75, 151, 152 distal colorectal adenomas, 153 
gastric cancer,93 T2DM, 154 cirrhosis,' 55 alcohol liver disease, I56 ' 157 progressive massive 
fibrosis, I58 macular degeneration, I59 alcoholic liver disease, I56 mood disorders, 160 
hypersensitivity to para-phenylene diatnine, I27 anlcylosing spondylitis, 161 rheumatoid 
arthritis 162, 163 or preeclampsia l" have been reported. These studies will now be 
discussed in more detail using disease sub-headings. 
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2.3.4.1 Breast Cancer 
-1 Eighteen original investigations 9708, 134-136, 165-167 have studied the association between 
SOD2 Ala 1 6Val SNP genotypes and breast cancer risk. Two reviews have also been 
published along with a recent meta-analysis examining cancer and the SOD Alal6Val 
genotype. 168-170 Twelve investigations reported an increased risk of breast cancer with 
- specific genotypes using multivariate analysis techniques. 9 108  7 	The largest study 
involved 1,265 Caucasian and 760 African American women with breast cancer and 
1,812 controls. 1°1 The investigators found that women with the Ala/Ala genotype who 
had either: 1) smoked for longer than 20 years (OR 2.3, 95% CI 1.3-4.1); 2) had chest 
exposure to high doses of radiation due to medical procedures other than breast cancer 
treatment or diagnosis (OR 1.5, 95% CI 1.0-2.2); or 3) had been exposed to ionizing 
radiation at work (OR 1.6, 95% CI 0.8-3.1), had an increased risk of the disease. 
However, the combined effects were weak. The frequency of the Ala/Ala genotype was 
25% in Caucasians and 18% in African Americans. 101 A similar result was also reported 
by Tamimi et al. 1°6 in a study of 2,173 participants, 968 of which had breast cancer. The 
study found a non-significant association (OR 1.41, 95% CI 0.77-2.60) between the 
Ala/Ala genotype and breast cancer in current smokers compared with the Val/Val 
genotype and non-smokers. 
A large study involving 1,125 Chinese women with breast cancer reported that those 
with the Ala/Ala genotype had a slightly increased, but not statistically significant, risk 
of the disease, if they had high levels of oxidative stress (OR 2.4, 95% CI 0.6-9.5), a 
low intake of antioxidants (OR 2.6, 95% CI 0.7-10.0) or a low intake of fruits and 
vegetables (OR 2.4, 95% CI 0.7-8.0). 98 However, the frequency of this genotype was 
only 2%, in keeping with the low prevalence of this genotype across Asian 
populations.98 Interestingly, Asian countries such as China and Japan have a reduced 
incidence of breast cancer compared with Europe and North America. 171 
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Other studies that examined pre and postmenopausal women included Egan et al. 1°7 
with a cohort of 470 American women, Ambrosone et al. 97 with 263 Caucasian women 
with breast cancer and a study involving 965 Finnish Caucasians, 483 of whom had 
breast cancer. 105 All studies reported minor relationships between breast cancer and the 
Ala/Ala genotype or Ala allele. Ambrosone et al. 97 reported an OR of 4.3 (95%CI 1.7- 
10.8) and a larger association amongst those who consumed low amounts of fruits and 
vegetables and other sources of dietary antioxidants (OR 6.0, 95%CI 2.0-18.2). 97 Egan 
et al. 1°7 reported an OR of 1.27 (95%CI 0.91-1.77) for an association between SOD2 
SNPs and breast cancer, providing limited support for an association between SOD2 
SNPs and breast cancer. The Finnish study reported that the Ala allele frequency was 
significantly greater in breast cancer patients (OR 1.5, 95% CI 1.1-2.0). The 
significance was increased in: 1) postmenopausal women who used oestrogen 
replacement therapy (OR 2.5, 95% CI, 1.3-4.8), and 2) women who smoked for longer 
than 15 years. 1°5 
The Ala allele was associated with an increased risk of breast cancer when alcohol 
consumption and body mass index (BMI) where considered. 99' 104 Slanger et al.99 found 
that women with the Ala allele (25%) had a significantly increased risk of breast cancer 
when their alcohol consumption was >19g per day, compared with those that consumed 
no alcohol. A small case-control study involving 187 women, 84 of whom had breast 
cancer, found no association between the disease and the Alal6Val SNP of SOD2 
(22%). However, after further analysis, those with the SOD2 Ala allele had a 
significantly increased risk of breast cancer if their BMI was greater than 24kg1m 2 and 
they had other SNPs (catechol 0-methyltransferase, COMT-L, involved in the 
metabolism of catecholamines and catecholestrogens, and CYP1B1*1 which produces 
cytochrome P450) (OR 1.42, 95%CI 1.04-1.93). 104  In male (n=11) and female (n=89) 
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breast cancer patients, the Ala/Ala genotype frequency was significantly greater in those 
with cancer (OR 2.5, 95% CI 1.394.54). 108 
A study examining breast cancer survival after treatment in 279 patients found no 
significant association between survival and SOD2 genotype. However, the Ala/Ala 
genotype did endow individuals with a slightly reduced hazard of all cause mortality.'
A study involving 118 females <36 years of age reported that those with the Val allele 
genotype (28%) had an increased risk of breast cancer compared to women with the 
Ala/Ala genotype (OR 2.90, 95% CI 1.39-6.14). 102 
The largest study that reported no association between the SOD2 Alal 6Val genotype 
and breast cancer was performed in 2,118 American women, 1,034 of whom had breast 
cancer. 135 The investigators found no significant relationship, even when risk factors for 
breast cancer, such as high BMI, smoking, alcohol and menopausal status were taken 
into account. 135 A study in Caucasian women found no association between breast 
cancer and the SOD2 Alal 6Val genotype, although the only variables taken into 
account were family history and menopausal status. 134 The risk of radiotoxicity in breast 
cancer patients was not related to the SOD2 SNP genotype. 165 Additionally, a small 
population study of 80 breast cancer patients found no significant association between 
the SOD2 genotype Ala! 6Val and postoperative tissue changes, such as breast size 
and/or shape. 167 Cox et al. 1°° also investigated the GPx1 Pro197Leu genotype in 
addition to SOD2 Alal 6Val genotype and found no association between SOD2 SNP 
and breast cancer when the SOD2 data was analysed alone. However, when both genes 
were studied, there was a significant association between breast cancer risk and the 
Ala/Ala genotype for SOD2 and the Leu/Leu genotype for GPx1 (OR 1.87, 95% CI 
1.09-3.19). 
Two studies have examined the SOD2 Alal 6Val SNP along with SNPs of estrogen- 
metabolising genes. Silva et al. 1°3 reported that Portuguese women with the Ala allele 
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genotype who never breast fed, had a non-significant decrease in the risk of breast 
cancer (OR 0.575, 95% Cl 0.327-1.011). Cheng et al. 136 reported no association 
between breast cancer and catechol estrogen metabolising genes (e.g., COMT) and the 
SOD2 Alal6Val SNP. 
Figure 2-1 summarises the relationship between SOD2 genotype and breast cancer. This 
quantitative overview is for illustrative purposes, to combine the statistical analysis of 
the major studies. Analysing the total population of cases and controls from each study 
reviewed, the Mantel-Haenszel OR and 95% CI were determined in relation to the 
Ala/Ala genotype compared with Ala/Val and Val/Val genotypes. The summary shows 
that there is a non-significant decrease in the risk of breast cancer in those with the 
Ala/Ala genotype compared with the Ala/Val and Val/Val genotypes (OR 0.97, 95% Cl 
0.90-1.05). Figure 2-1 also illustrates the significant heterogeneity across the studies, 
possibly due to true variation in genetic expression. However, a more likely explanation 
relates to the limitations of observational methodology (e.g., differences in unrecorded 
confounding factors, or publication bias) and our limited secondary analysis of the 
published reports. 
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Figure 2-1: Studies investigating the relationship between the Ala/Ala genotype of the SOD2 
Ala9Val and occurrence of breast cancer: a quantitative overview of results 
$ The appropriate data was not published 
• The size of the square indicates the population size in the study 
• The result of all the studies with the top and bottom points are an estimate of effect size and the left 
and right points show the 95% CI 
Combined Mantel-Haenszel Odds Ratio: 0.97 (0.90 to! .05). Chi-squared test for homogeneity: 56.25; 
p<0.001 
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2.3.4.2 Prostate Cancer 
Nine studies examined prostate cancer in relation to the SOD2 Alal6Val SNP. In the 
largest, Kang et al! " examined SNPs in SOD!, SOD2 and SOD3 in 3,162 Americans, 
including 1,213 Caucasians and 107 African Americans diagnosed with prostate cancer. 
This study found that Caucasians with the Ala/Ala (OR 1.28, 95% CI 1.03-1.60) and 
Val/Ala genotype (non-significant) had an increased risk of prostate cancer when 
compared with patients with Val/Val genotype. This association was not found in 
African Americans, but the patient population studied was smaller. This study also 
found in Caucasians that there was an association between the incidence of prostate 
cancer and a low dietary intake of vitamin E (OR 1.56, 95% CI 1.11-2.20). Seven other 
studies found that prostate cancer was significantly associated with the Ala/Ala or Ala 
allele genotype when the population was stratified into either disease stages of prostate 
cancer or other factors (e.g., alcohol consumption, age and antioxidant levels). Three 
studies reported that the Ala/Ala or Ala allele polymorphism were associated with high-
grade tumours or an aggressive form of prostate cancer. 11I, 112, 116 One study found an 
association with the Ala/Ala genotype and high grade tumours, but only when the high 
selenium levels were taken into account (OR 1.89, 95% CI 1.01-3.56). 112 Woodson et 
al!" also reported that high-grade prostate tumours were significantly associated with 
the Ala allele (OR 2.72, 95% CI 1.15-6.40). An aggressive form of prostate cancer was 
reported to be significantly associated with Ala/Ala genotype, although only when the 
men had low levels of the antioxidant, lycopene (RR 3.10, 95% CI 1.37-7.02). 116 Ergen 
et al. 117 reported in a study involving 100 participants, of whom 50 had prostate cancer 
that the Ala/Ala genotype frequency was significantly increased in patients compared 
with controls (OR 1.14, 95% CI 1.02-1.25). In fact, none of the 50 controls possessed 
the Ala/Ala genotype. The fifth study found that Ala/Ala was associated with a greater 
risk of prostate cancer if diagnosed under the age of 65 (OR 5.20, 95% CI 0.92- 
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29.26). 113 The sixth study, involving 187, mainly Caucasian patients, reported that the 
Ala/Ala genotype frequency was increased significantly in those with prostate cancer 
(OR 1.65, 95% CI 1.03-2.66). The significance of the association was increased in 
patients that smoked and had a SNP in the N-acetyltransferase 1 (NATI isoform) 
gene. 115 A small study reported that the frequency of the Ala/Ala genotype was 
significantly increased in all prostate cancer patients compared with controls (OR 2.5, 
95% CI 1.394.54). 108 
A larger contradictory study involving 724 men with prostate cancer, found that there 
was no association between prostate cancer and the SOD2 genotype, even in patients 
under the age of 65, those that took vitamin supplements and those with other risk 
factors for prostate cancer. 172 Wang et al!" performed a meta-analysis of 34 studies 
that examined the association between SOD2 Alal6Val polymorphism and cancer. This 
meta-analysis failed to find an association between the Alal6Val SNP and the risk of all 
cancers. However, there was a significant association between Ala/Ala and Ala/Val 
genotypes and prostate cancer compared with Val/Val (OR1.2, 95% CI 1.0-1.3). 
In summary, a number of studies have shown prostate cancer is associated with the 
Ala/Ala genotype. However, each study stratified the population into specific groups in 
order to reveal this relationship. Figure 2-2 provides a summary of the results of these 
studies and demonstrates a significant association between prostate cancer and the 
SOD2 Ala/Ala and Val/Ala genotypes (OR 1.16, 95%CI 1.03-1.32). 
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Figure 2-2: Studies investigating relationships between the Val/Ala and Ala/Ala genotype 
compared with Ala/Ala of the SOD2 Ala9Val SNP and occurrence of prostate cancer: a 
quantitative overview of the results 
$ The appropriate data was not published 
• The size of the square indicates the population size in the study 
• The result of all the studies with the top and bottom points are an estimate of effect size and the 
left and right points showing the 95% Cl. Combined Mantel-Haenszel Odds Ratio: 1.16 (1.03 
to 1.32). Chi-squared test for homogeneity: 18.77; p<0.0272 
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2.3.4.3 Other Cancers 
Twenty-one studies have investigated the relationship between the SOD2 Alal 6Val 
, 93, 109, 118-120, 130, 137-146, 149-152 SNP and other cancers. 75 	 Wang et al. 151 found that 
individuals with the Val allele had an increased risk of lung cancer if there was low or 
no asbestos exposure compared to high exposure (OR 2.14, 95% CI 1.52-3.01), 
although the small number in the high asbestos exposure group limited the findings. The 
largest case-control study- involved 2,168 participants, of whom 935 had lung cancer. 
There was an increased risk of lung cancer in individuals with the VaVVal genotype 
when they had two other polymorphisms, viz, in p53 and in the X-ray repair cross-
complementing group 1 (XRCC1) gene that encodes a protein involved in DNA repair 
(OR 2.54, 95% CI 1.38-4.68). These two SNPs had previously been linked to an 
increased risk of lung cancer. 119 A similar result was reported in a study of 150 
participants, including 100 with lung cancer. This study examined lung cancer cell types 
and found that the Val/Val genotype frequency was significantly greater than the 
Ala/Ala and Ala/Val genotypes in those with squamous cell cancer. I18 Three studies of 
chronic obstructive pulmonary disease reported no association with the SOD2 
genotype. 138-140 A study by Landi et al. 13° also investigated 80 malignant pleural 
mesothelioma patients and 349 controls and found an increased risk of the disease in 
patients that carried the Ala/Ala genotype (OR 3.07, 95% CI 1.55-6.05). Although this 
result is in disagreement with those of the larger studies (1,746 cases when combined), 
Landi and co-workers 13° examined a specific form of cancer, malignant pleural 
mesothelioma that is mainly caused by asbestos exposure. 
There have been two smaller studies, in specific ethnic groups, viz, Taiwanese 152 and 
Chinese75, the largest involving 243 cases, which found no association between lung 
cancer and the SOD2 Alal6Val SNP.75 ' 152 
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An increased risk of bladder cancer has also been associated with the Alal6Val SNP in 
SOD2. The relationship was found in heavy smokers with the Val/Val genotype (OR 
2.24, 95% CI 1.15-4.36). 1° However, Inchimura et al. 137 performed a similar study in 
Japanese subjects who had a very low frequency of the Ala/Ala genotype and found no 
significant association between this SNP and the risk of bladder cancer. 
A large case-control study involving 1,172 patients, investigated the associations 
between thirteen SNPs, including the SOD2 Alal6Val SNP and the risk of non-Hodgkin 
lymphoma. The total cohort was 2,154 and the authors reported no significant 
association with non-Hodgkin lymphoma. However, a significant association was 
observed between B-cell lymphomas and individuals with the Ala/Ala SOD2 genotype 
(OR 1.3, 95% Cl 1.0-1.6). 149 A similar sized case-control study (928 cases and 1,446 
controls) recruited from the USA and UK, found no association between SOD2 
Alal6Val SNP genotypes and non-Hodgkin lymphoma. 15° 
Eighty-nine patients with acute myeloid leukaemia were investigated to determine 
whether there was an association between the SOD2 Ala! 6Val SNP and survival after 
treatment. This non case-control study found that patients with the Ala/Val genotype 
had a greater chance of survival compared to those with the Ala/Ala genotype (95% CI 
19.6-52.4). 120 The investigators also reported that patients with the Ala/Ala genotype 
had significantly worse outcomes after treatment compared to patients with Val/Val 
genotype (OR 2.0, 95% CI 1.1-3.5). Finally, other forms of cancers have been studied 
including gastric, oesophageal, pancreatic, ovarian and skin cancer, with all studies 
reporting no association with SOD2 genotypes.93 ' 141446 
2.3.4.4 Diabetes 
Seven studies have investigated the relationship between the SOD2 genotypes and co- 
morbidities of T1DM or T2DM. A study conducted within a Korean population 
reported an association with diabetic macular edema and the Ala allele in those with 
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diabetic retinopathy (n=130) (OR 1.59, 95% CI 1.02-2.02). 122 However, there was no 
association with the development of diabetes itself.' In the same cohort, the authors 
reported that the Ala allele was significantly different between T2DM patients with 
albuminuria, compared with those without (p<0.05), but there was no difference 
between the SOD2 genotypes of T2DM patients and controls. 124 In contrast to these two 
investigations, another study showed that the Val/Val genotype in 12DM patients was 
associated with diabetic retinopathy (OR 2.1, 95% CI 1.2-3.4). 125 Two other studies 
reported that the Val/Val homozygote genotype or the Val allele was associated with 
diabetic nephropathy. 121 ' 123 One study examined T1DM and found an increased risk of 
diabetic nephropathy with the ValNal genotype (OR 1.32, 95% CI 1.00-1.74). 121 The 
second study examined patients with T2DM and reported that the Val/Val genotype was 
significantly higher in those with nephropathy (p=0.0057). 121 ' 123 A smaller study, that 
examined patients with either 11DM or 12DM, reported a greater frequency of the 
Val/Val genotype in these patient groups compared with a controls (p<0.05). 126 Finally, 
a study in 91 12DM patients found no association between SOD2 genotype and 
coronary artery calcium score (used to determine the presence of vascular calcification 
seen in atherosclerotic cardiovascular disease). 154 Although all of these studies 
examined patients with diabetes, they investigated different co-morbidities and hence, 
the results are difficult to compare. 
2.3.4.5 Cardiovascular Disease (CVD) 
Three studies have examined the relationships between SOD2 Alal6Val SNP genotypes 
and biological measurements associated with CVD. The largest, involving 989 
participants, found a significant relationship between carotid artery intima-media 
thickness (CIMT), a measure of atherosclerotic burden, and the Val allele in women that 
had high levels of low-density lipoprotein (LDL) cholesterol (p=0.03). 72 The second 
study examined 217 patients with haemochromatosis and 212 controls and reported that 
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those with haemochromatosis and the Val allele had an increased risk of 
cardiomyopathy compared with those with the Ala allele. However, only 27 patients had 
cardiomyopathy, and eleven (30%) of these had the ValNal genotype (p=0.0006). 23 The 
third study involved 252 participants and examined oxidised LDL, a marker of 
oxidative stress and a biomarker for the development of atherosclerosis. The 
investigators found that in patients with oxidised LDL <0.5nmol/mg, the Ala/Val and 
Val/Val genotypes were associated with increased levels of oxidised LDL compared 
with Ala/Ala genotype in the same group (OR 3.61, 95% CI 1.42-9.17). 21 
2.3.4.6 Liver Disease 
The SOD2 Val/Val genotype was found more frequently in 63 patients diagnosed with 
non-alcoholic steatohepatitis (NASH) when compared with 150 controls (OR 2.49, 95% 
CI 1.17-5.32). 129 A study that examined hereditary haemochromatosis and chronic 
hepatitis C to determine the development of cirrhosis in these groups, concluded that 
SOD2 genotypes were not markers for the development of cirrhosis. I55 A study of 176 
heavy drinkers, of whom 100 had alcoholic liver disease (ALD) and 76 controls, 
reported that there was no association with the SOD2 Alal 6Val SNP and risk of 
ALD. I56 Another study involving 218 patients with ALD and 218 heavy drinkers 
without ADL also reported no association between SOD2 SNP and the development of 
ALD. 152 
2.3.4.7 Neurological and Mental Health 
There have been two studies investigating whether the SOD2 Alal6Val SNP could be 
used to predict the occurrence of tardive dyskinesia in schizophrenic patients on 
antipsychotic therapy. There was no association seen when this SNP was examined on 
its own. However, when both studies included either, 1) a dopamine D3 receptor SNP 132 
or 2) a NAD(P)H dehydrogenase quinone oxidoreductase 1 (NQ01) SNP, involved in 
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the reduction of quinones, 133 a significant association with the Val/Val genotype was 
found in patients with and without tardive dysldnesia ((1) x 2=8.09, degrees of freedom 
=3, pA.04) and ((2) x2=8.00, degrees of freedom =3, p-1042). 132 ' 133 In a study 
examining 80 patients with a major depressive disorder, 61 with a bipolar disorder and 
106 controls, it was found that there was no association between any of these mood 
disorders and the SOD2 Alal6Val SNP. 16° 
2.3.4.8 Other conditions 
A study examining hypersensitivity to the skin irritant dye, para-phenylene diamine, 
found that older females with the Ala/Ala genotype had an increased risk of dermatitis 
(OR 1.5, 95% CI 0.7-2.34). 127 In a small study (35 females and 37 males), the Ala 
allele was found to be associated with an increased risk of being diagnosed with 
sporadic motor neurone disease, particularly in females (OR 5.5, 95% CI 1.5-19.9). 131 A 
case-control study of patients with brain tumours (glioma, meningioma and acoustic 
neuroma), found that the Ala allele was associated with an increased risk of acoustic 
neuroma (OR 2.0, 95% CI 1.0-4.2). 96 The Ala allele was also found to be increased in 
black South African patients with diffuse cutaneous systemic sclerosis (OR 2.11, 95% 
CI 1.1-4.05). 128 Another study reported that the Val/Val genotype was significantly 
higher in patients with Behcet's disease (blood vessel inflammatory disease) compared 
with controls (OR 2.41, 95% CI 1.09-5.32). 110 Seven studies found no association with 
SOD2 Alal6Val SNP genotypes and diseases including preeclampsia, 164  distal 
colorectal adenomas, 153 progressive massive fibrosis, 158 ankylosing spondylitis 161 and 
rheumatoid artritis. 162 ' 163 However, one of these studies found that the autoimmune 
disease, Sjogren's syndrome, was associated with the Val/Val genotype. 163 
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2.3.4.9 Summary 
The majority of studies investigating the relationships between the SOD2 Alal6Val 
genotypes and disease have been conducted in breast cancer with most showing an 
association with the Ala/Ala genotype. A combined quantitative overview indicates that 
this confers a slightly reduced risk of breast cancer in people with this genotype. 
Although the Ala/Ala genotype has been shown to be associated with an increased risk 
of prostate cancer, a quantitative overview showed no such association. In a smaller 
number of studies, the Ala allele or the Ala/Ala genotype have been associated with 
non-Hodgkin lymphoma, brain tumours, motor neurone disease, malignant pleural 
mesothelioma and systemic sclerosis. Although individuals with the Val/Val genotype 
or the Val allele have been shown to have an increased risk of bladder cancer, NASH, 
leukaemia and co-morbidities in T1DM and T2DM, other studies do not support these 
relationships. In the three studies examining relationships with CVD, all have found a 
strong positive association with the Val allele and markers of CVD risk. 
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Table 2-1: Studies investigating relationships between genotypes of the SOD2 Alal6Val SNP and disease 
Condition Reference 
Participants Genotype 
Cases/Controls 
Val/Val 
Cases (n MD/ 
Controls (n 
Val/Ala 
Cases (n 1%])/ 
Controls (n 1%1) 
Ala/Ala 
Cases (n MI)/ 
Controls (n 
Breast Cancer Millikan, et acol Caucasians 760/1,135 
273 [21]/266 [23] 681 [54]1586[52] 311[25]/283[25] 
African American 259[34]/196 [29] 372[49]/357[53] 129[17]/124[18] 
760/677 
Breast Cancer Cox, et al.'" 1,262/1,533 Data not given Data not given Data not given 
Breast Cancer Cai, et al.98 1,125/1,197 831[74]/884[74] 266[24] /290[24] 28[2]/23[2] 
Breast Cancer Gaudet, et ai m 1,034/1,084 253[25]/264[24] 511[49]/539[50] 270[26]/281[26] 
Breast Cancer Tamimi et al. 198 968/1,205 255[26]/297[25] 468[49/612[51] 245[25]/296[24] 
Breast Cancer Slanger, et al." 614/1,080 144[23]/263[24] 318[52]/528[49] 152[25]/289[27] 
Breast Cancer Cheng, et a1. 136 469/740 343[73]/545[74] 115[25]/183[25] 11[2]/11[1] 
Breast Cancer Egan, et al. 197 470/497 120[21]/130[26] 250[53]/240[49] 118[25]/127[26] 
Breast Cancer Mitrunen, et. 
al. 1°5 
483/482 153[32]/124[26] 231[48]/255[53] 98[20]/100[21] 
Breast Cancer Silva, et al.' 93 241/636 59[24]1109[22] 146[61]/339[60] 36[15]/188[18] 
Breast Cancer Knight, et al. 134 372/399 107 [27]/ 90[24] 187 [47]/ 195 [52] 105 [261/ 87 [23] 
Finding 
Ala/Ala had a weak association with breast cancer 
with specific environmental factors (smoking, 
radiation) 
Ala/Ala associated with breast cancer when 
combined with another SNP in GPx1 (OR 1.87, 95% 
CI 1.09-3.19) 
Ala/Ala associated with breast cancer in patients 
with elevated oxidative stress and a low intake of 
antioxidants (OR 2.4, 95% CI 0.7-8.0) 
No significant association. 
Ala/Ala genotype was associated with a significant 
increase risk of breast cancer in current smokers 
compared with Val/Val genotype and non-smokers 
(OR 1.41, 95% CI 0.77-2.60) 
Ala allele significantly associated with breast 
cancer when patients consumed high quantities of 
alcohol 
No significant association. 
Val/Ala had a minor association with breast cancer 
(OR1.8, 95%CI 1.0-3.1) in premenopausal women 
Ala allele to be associated with increase risk of 
breast cancer (OR 1.5, 95% CI 1.1-2.0) 
Ala allele had minor non significant association 
with decreased risk of breast cancer in patients that had 
never breast fed (OR 0.575, 95% CI 0.327-1.011, 
p=0.054). 
No significant association. 
tr.) 
■.) 
Condition Reference 
Participants Genotype 
Cases/Controls 
Val/Val 
Cases (n [%])/ 
Controls (n IN) 
Val/Ala 
Cases (n r/01)/ 
Controls (n IM1) 
Ala/Ala 
Cases (n [%])/ 
Controls (n 
Finding 
Breast Cancer Ambrosone, et 
al." 
266/295 39[14]/63[21] 137[52]/169[57] 90[34]/63[21] Ala/Ala associated with breast cancer in 
premenopausal patients (OR=4.3, 95%CI 1.7-10.8) and 
larger in those consuming low amounts of fruit and 
vegetables (OR = 6.0, 95%CI 2.0-18.2). 
Breast Cancer Bica, et. al. 1°8 100/372 Ala/Ala genotype was associated with a significant 
Male 11/155 M 5[46]/42[27] M 5[45]/105[68] M 1[9]/8[5] increase in breast and prostate cancer when all patients 
Female 89/217 F 24[27]/52[24] F 51[57]/147[68] F 14[16]/18[8] analysed together (OR 2.5, 95% CI 1.39-4.54, 
p=0.002). 
Breast Cancer Ahn, et al. 165 (cases) 446 113[26] 204[48] 111[26] No significant association. 
Breast Cancer Ambrosone, et 
al •166 
279 67[25] 137[51] 63[24] No significant association. 
Breast Cancer Bergman, et 
al. 162 
118/174 33 [28]/43 [25] 73 [62]/88[50] 12[10}/43[25] Val allele associated with increased risk of breast 
cancer in females <36 years old (OR 2.90, 95% CI 
1.39-6.14, p=0.002) 
Breast Cancer Kocabas, et 84/103 28[33]/28[27] 38 [45]/40 [39J 18[22]/38 [37] Ala allele significantly associated with breast 
cancer in patients with and increased BMI and other 
genotypes (OR 1.42, 95%CI 1.04-1.93) 
Breast Cancer Green, et al. 167 80 13 [33]/8 [22] 17[44]/22[61] 9[23]/6 [17] No significant association 
Tissue damage 39/ 
No tissue damage 
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Prostate Cancer Kang, et al)" 1,320/1,842 
(Caucasians: 1,213 
275[24]/376[27] 578[50]/686[50] 297[26]/320[23] Ala/Ala and Ala/Val is associated with prostate 
cancer in Caucasians (OR 1.28, 95% Cl 1.03-1.60; 
/1,433; African 31[30]/122[31] 57[55]/194[49] 15[15]/79[20] 1.28, 95% CI 0.97 - 1.42, Ptrend=0.028) 
Americans: 107/40 
9) 
Prostate Cancer Choi, et al. 172 724/1,474 128[25]/356[25] 258[511/683[49] 116[23]/349[25] No significant association. 
Prostate Cancer Li, et al. u2 567/764 132[23]/190[24] 288[51]/379[50] 147[26]/195[26] Ala/Ala associated with more aggressive form of 
prostate cancer (RR 1.89, 95% Cl 1.01-3.56, p=0.01) 
00 
Condition Reference 
Participants Genotype 
Cases/Controls 
Val/Val 
Cases (n r/o1)/ 
Controls (n l°41) 
Val/Ala 
Cases (n [%1)/ 
Controls (n IN) 
Ala/Ala 
Cases (n 1%1)/ 
Controls (n 
Finding 
Prostate Cancer Mikhak, et 
al.' 16 
612/612 156[24]/162[25] 320[50]/331[51] 166[26]/159[24] Ala/Ala was associated with aggressive prostate 
cancer in men with low lycopene status (RR 3.10, 95% 
CI 1.37-7.02, p=0.02) 
Prostate Cancer Bica, et al. 1°8 51/372 10[19]/94[25] 32[63]/252[68] 9[18]/26[7] Ala/Ala genotype was associated with significant 
increase in prostate and breast cancer when all patients 
analysed together (OR 2.5, 95% Cl 1.39-4.54, 
p=0.002). 
Prostate Cancer Woodson, et 197/190 43[22]/49[26] 98[49]/102[53] 58[29]/40[21] Ala/Ala associated with high grade tumour in 
prostate cancer (OR 2.72, 95% CI 1.15-6.40, p=0.02) 
Prostate Cancer Iguchi et al. 115 187/175 41[221/40[23] 86[46]196[55] 60[3439[22] Ala/Ala was significantly associated with prostate 
cancer (OR 1.65, 95% CI 1.03-2.66) 
Prostate Cancer Arsova- 
Sarafinovska, 
et al: 13 
85/151 19[22]/41[27] 46 [54]/73 [48] 20[2037[25] Ala/Ala genotype showed an increased risk of early 
onset prostrate cancer if diagnosed under 65 years (OR 
5.20, 95% CI 0.92-29.26, p=0.05) 
Prostate Cancer Ergen, et al. 117 50/50 19[38]/32[64] 25[50]/18[36] 6[12]/0[0] Ala/Ala frequency significantly higher in prostate 
cancer patients (OR 1.14,95% CI 1.02-1.25, 
p=0.0012) 
Lung Cancer Liu, et al. 119 935/1,233 208[27]/322[23] 472[51]/626[51] 255[24285[26] ValNal associated with lung cancer in the presence 
of two other SNPs (OR 2.54, 95% CI 1.36-4.68) 
Lung Cancer Wang, et al. 151 911/957 173[21]/255[27] 513[51]/482[50] 225[28]/220[13] No significant association, although the Val allele 
showed an association with increased risk of lung 
cancer with low or no asbestoses exposure (OR 2.14, 
95% CI 1.52-3.01) 
Lung Cancer Lin, et al. 152 198/332 139[70]/233[70] 59[30]/81[30] Val/ Ala and No significant association. 
Ala/Ala 
Data was pooled 
together 
Lung Cancer Ho, et al. 75 234/239 176[75]/180[75] 58[25]/52[221 0[0]/7[3] No significant association. 
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Participants Genotype 
Condition Reference 
Cases/Controls 
I23[23]/276[25] 	273[50]/546[48] 147[27]/308[27] 	No significant association 
Val/Val 
Cases (n [%])/ 
Controls (n [%]) 
Val/Ala 
Cases (n [%])/ 
Controls (n [%]) 
Ala/Ala 
Cases (n [%])/ 
Controls (n [%]) 
Finding 
Ovarian Cancer 
Skin Cancer 
Oesophageal 
Cancer 
Oesophageal 
Cancer 
Oesophageal 
Cancer 
Gastric Cancer 
Acute Myeloid 
Leukaemia 
Johnatty, et 
a l . 141 
Han, et al. 142 
Sun et al. I43 
Di Martino et 
al. 144 
Murphy, et 
al."5 
Martin, et al. 93 
Koistinen, et 
al . 120 
543/1,130 
805/873 
Cancer patients 
170 
Heavy drinkers 
160 
Healthy controls 
400 
490/94 
396/223 
274/361 
89 
184[24]/196[24] 
35[20] 
43[27] 
139[35] 
128[26]/20[21] 
93 [23]/60[27] 
72[26]/99[27] 
20[22] 
402[52]/425[51] 
88[52] 
80[50] 
211[53] 
234[48]/39[42] 
196[49]/113[51] 
153[56]/209[58] 
49[56] 
187[24]/212[25] 
47[28] 
37[23] 
50[12] 
122[25]/34[37] 
107[27]/48[22] 
49[18]/53[15] 
20[22] 
No significant association 
No significant association. 
24/23 No significant association Li, et al. 146 Pancreatic Cancer 10[421/8[351 11[46]/10[43] 3[121/5[221 
255[27]/130[24] 	457[48]/284[51] 
1,510 
955/555 
79[66] 
220[72] 
52[29] 
206[84]/158[70] 	Val/ Ala and 
Val/Val 
(Data pooled) 
36[30] 
80[26] 
90[50] 
5[4] 
6[2] 
38[21] 
Val/Val genotype significantly different in both 
T1DM and T2DM compared with controls (p<0.05) 
Val/Val had an increased risk of diabetic 
239[25]/140[25] 	nephropathy in smokers (OR 1.32, 95% CI 1.00-1.74, 
p=0.049) 
85[15]/29[29] 
Val/Val genotype was significantly higher in 
diabetic nephropathy (p=0.0057) 
T1DM 
(with/without 
diabetic 
nephropathy) 
T2DM 
Diabetic 
Nephropathy 
T1DM and 12DM 
Mollsten, et 
al . 121 
Nomiyama, et 
al.' 23 
Flekac, et al l 26 
478/261 
T1DM 120 
T2DM 306 
Control 180 
No significant association 
No significant association 
No significant association. 
AlaNal patients found to have a greater chance of 
survival (95% CI 19.6-52.4, p=0.02). 
Condition 
Participants Genotype 
Reference 
Cases/Controls 
Val/Val 
Cases (n [%])/ 
Controls (n [%]) 
Val/Ala 
Cases (n I%])/ 
Controls (n [%]) 
Ala/Ala 
Cases (n [%])/ 
Controls (n [%]) 
T2DM Lee, et al l" 371/178 314[82]/146[84] 57[18]/32[15] Val/ Ala and 
(Albuminuria) Ala/Ala 
(Data pooled) 
T2DM Lee, et al.' 22 304/192 243[79]/152[79] 61[20]/40[20] Val/ Ala and 
(diabetic macular 
edema) 
Ala/Ala 
(Data pooled) 
T2DM Petrovic, et 426 
(with/without 
diabetic 
retinopathy) 
283/143 63[22]/51[35] 140[49]/69[48] 80[28]/23[16] 
T2DM 
(coronary artery 
calcium score) 
Nemoto et 
al.'" 
91 No data given No data given No data given 
Carotid Kakko, et al." 989 265[27] 492[50] 232[23] 
Athersclerosis 
Cardiomyopathy 
(cases=hereditary 
haemochromatosi 
s) 
Valenti, et al." 217/212 37[17]/51[24] 132[60]/118[56] 48[23]/43[20] 
CVD 
(cases=LDL? 
0.5nmol/mg 
control= LDL< 
Gottlieb, et 
al.71 82/170 49[6084[49] 26[32]/44[26] 7[8]/42[25] 
0.5nmol/mF) 
Alcoholic Liver Stewart, et ALD 281 72[25] 156[56] 53[19] 
Disease (ALD) al. 152 Non- ALD 218 58[27] 109[50] 51[23] 
Controls 244 64[26] 125[51] 55[23] 
Non-Alcoholic 
Steatohepatits 
Namikawa, et at m 63/150 [84]/[68] [11]/[29] [5 ]/[3 ] 
(NASH) 
Finding 
An association was found in frequency with Ala 
allele between albuminuria +/- (p<0.05). However 
there was no difference between T2DM and controls 
Ala allele associated with diabetic macular edema. 
However not associated with the development of 
12DM (OR 1.59, 95% CI 1.02-2.02, p=0.03) 
ValNal genotype was found to be an risk factor for 
diabetic retinopathy (OR 2.1, 95% Cl 1.2-3.4, 
p=0.006) 
No significant association. 
Val allele was associated with higher IMT in 
females with high low-density lipoproteins (p=0.03) 
Val allele showed an increased risk of 
cardiomyopathy (p=0.0006) 
ValNal and AlaNal genotypes had higher LDL in 
the control group (OR 3.61, 95% Cl 1.42-9.17) 
No significant association. 
ValNal frequency higher in NASH patients 
compared with controls (OR 2.49, 95% Cl 1.17-5.32, 
p=0.016) 
ts.) 
Participants Genotype 
Condition Reference Val/Val Val/Ala Ala/Ala Finding Cases/Controls Cases (n rol)/ Cases (n MD/ Cases (n Mop/ 
Controls (n PA1) Controls (n [%]) Controls (n [%]) 
ALD Martins, et a l . 156 100/75 23[23]/19[25] 55[55]/37[50] 22[2419[25] No significant association. 
Cirrhosis Stickel, et al. 155 Hereditary 
Haemochromatosi 32[20] 94[60] 31[20] No significant association found in any of the 
s 157 69[28] 136[48] 80[24] groups 
Chronic Hepatitis- 36[22] 81[51] 43[27] 
C 285 
Controls 160 
Schizophrenia Pae et al)" 107/106 73[68]/72[68] 34[32]/34[32] 0/0 
(with and without 
Tardive 
Val/Val genotype frequency was significantly 
different in with schizophrenia patients with TD 
Dyskinesia (TD)) (x2=8.0, degrees of freedom =3, p=0.042) 
Schizophrenia 
(with and without 
Zhang, et al. 132 42/52 30[73]/33[63] 12[29]/19[37] 0/0 The presence of another polymorphism and the Val 
allele was associated with TD in schizophrenia patients 
TD) (x2=8.09, degrees of freedom =3, p=0.04) 
Mood Disorders Pae, et al. 16° 141/106 80[57]/68[641 60[42]/38[36] 1[1]/0 No significant association. 
Asthma HoIla, et al. 147 299/327 78[23]/78[26] 150[51]/168[50] 71[241/81[23] No significant association. 
Asthma Mak, et al. 148 25 1/3 16 192[77]/233[76] 59[23]/74[24] Val/ Ala and No significant association. 
Ala/Ala 
(Data was pooled 
together) 
Brain Tumour Rajaraman, et 
a1.96 
565/494 129[25]/122[27] 162[51]/220[49] 123[24]/109[24] Ala allele showed an increase of acoustic neuroma 
(OR 2.0, 95% CI 1.0-4.2, p<0.05) 
Distal Colorectal Levine, et al.' 53 456/495 139[27]/140[25] 209[40]/234[42] 108[21]/121[22] No significant association. 
Adenomas 
Hypersensitized to 
Para-phenylene 
Brans, et al. 127 157/201 43 [26]/46[25] 73[471/104[52] 41[27]/51[23] Association found with Ala allele in women over 
the age of 45yrs (OR 1.5, 95% CI 0.7-2.34) 
Rheumatoid Mattey, et al. 162 153/218 42[24]/61 [28] 73[48]/112[51] 38[28]/45[21] No significant association. 
Arthritis 
Condition 
Participants Genotype 
Reference 
Cases/Controls 
Val/Val 
Cases (n [%])/ 
Controls (n 
Val/Ala 
Cases (n r/01)/ 
Controls (n f%i) 
Ala/Ala 
Cases (n MI)/ 
Controls (n PAD 
Finding 
Rheumatoid Yen, et al. 163 112/96 71[63]/61[63] 34[30]/32[33] 7[6]/3[3] No significant association. 
Arthritis 
Risk of Kim, et al. 164 106/115 78[74]/83[72] 26[24]/30[26] 2[2]/2[2] No significant association. 
Preeclampsia 
Motor Neuron 
Disease (MND) 
Van 
Landeghem, et 
72/136 16[22]/46[34] 35[49]/69[51] 21[29]/21[15] Ala allele associated with a higher risk of MND, 
especially in females (OR 5.5, 95% Cl 1.5-19.9) 
Macular 
Degeneration 
Esfandiary, et 
at 159 
94/95 44[47]/47[50] 44[47]/41[43] 6[6]/7[7] No significant association. 
Behcet Disease Nakao, et al." ° 78/107 68[87]/79[74] 9[12]/27[25] 1[1]/1[1] Val/Val genotype was found to have an association 
with Behcet disease (OR 2.41, 95% CI 1.09-5.32, 
p=0.03) 
Ankylosing Yen, et al. 161 70/93 43[62]/60[65] 26[37]/30[32] 1[1]/3[3] No significant association. 
Spondylits 
Progressive Yucesoy, et at 3 50/3 50 90[30]/88[27] 138[47]/168[51] 69[23]/72[22] No significant association. 
Massive Fibrosis 
(in coal miners) 
158 
Systemic Sclerosis 
(Scleroderma) 
Tikly, et al: 28 51/61 16[31]/28[45] 22[43]/23[37] 14[27]/11[18] A trend of Ala allele frequency increased in diffuse 
cutaneous systemic sclerosis patients (OR 2.11,95% 
Cl 1.1-4.05) 
2.3.5 Glutathione Peroxidase (GPx) Isoforms and SNPs 
Various isoforms of GPx are discussed in section 1.2.3. However, a search of NCBI 
found the following numbers of GPx isoform SNPs in humans: 46 in GPxl, 73 in GPx2, 
120 in GPx3, 88 in GPx4 and 93 in GPx5 (see Appendix A5.1. for a link to GPx SNPs). 
The GPx1 isoform has four SNPs that change the amino acid produced and only one has 
been studied in relation to diseases in humans, rs1050450. This is a C>T mutation that 
changes the amino acid at position 197 (noted in the NCBI database as position 200 and 
it has also been recorded to be at position 198) the amino acid changes from proline 
(Pro) to leucine (Leu). The GPx1 Pro197Leu SNP has been the most investigated SNP 
in the GPx enzymes in relation to disease involving twenty studies. Therefore, this SNP 
will be the main focus of this part of the review. 
However, another SNP, which does not code for an amino acid in GPxl, is rs1800668, 
and is present in exon 1 in the 5' URT section. This SNP, a C>T substitution, has been 
investigated in relation to oesophageal cancer along with 61 other SNPs in specific 
enzymes involved in DNA repair. It was found that specific genotypes were associated 
with an increased risk of cancer. I74 A study that examined 325 SNPs included the GPx1 
SNP, rs3448. This SNP is located in the 3' end of the gene and is a C>T mutation that 
does not code for an amino acid. The study examined all the SNPs in relation to non-
pathological cognitive ageing and reported that only one specific SNP, present in the 
amyloid precursor protein gene, had a significant association with cognitive ageing. I75 
Three SNPs of the GPx2 isoform have been identified in the amino acid coding region 
of exon 2. However, none of these have been studied in relation to disease. The GPx3 
isoform has three SNPs that are present in amino acid coding regions of exons 1 and 4, 
although they also have not been investigated in relation to disease. However, two 
45 
studies that focussed on eight GPx3 SNPs in the promoter region found that the SNPs 
were associated with an increased risk of stroke and thrombosis. 176' 177 
The GPx4 isoform has the largest number of SNPs identified within exon regions - three 
in exon 1, two which are silent, and the third that is a missense mutation with a A>G 
substitution changing the amino acid at position two from asparagine (Asn) to serine 
(Ser). However, this mutation has not yet been studied in relation to any disease. 
Similarly, two other missense mutations in exons 3 and 7, have not been studied in 
relation to disease. Other silent mutations are also found in exons 2, 4, 5 and 7. The 
silent mutation identified in exon 4, rs1042863, is a T>C substitution that changes the 
amino acid at position 122, with glycine (Gly) being unchanged. This SNP was reported 
to be associated with all cause mortality in patients diagnosed with breast cancer. I78 
However, another study of breast cancer survivors examined 54 polymorphisms in 
different antioxidant genes including GPx4. This GPx4 SNP is a silent mutation in exon 
7, rs713041, that changes a C>T at position 220 and a C>G mutation in the 5' region, 
rs757229. The study reported that both SNPs were associated with mortality in breast 
cancer patients. 178 A SNP that has yet to be cited in the NCBI database, a C>T mutation 
at position 718 of GPx4, has been linked with colorectal cancer. 179 This SNP has also 
been associated with increased leukotriene biosynthesis with C/C genotype compared 
with TIC and T/T genotypes. I80 In colorectal adenoma, there were no relationships 
between six SNPs in GPx isoforms 1-4. 181 In GPx5, only four of the 66 identified SNPs 
are in amino acid coding regions and none of these mutations have been studied in 
relation to disease. 
2.3.6 GPx1 Pro197Leu and Disease 
Twenty studies have investigated the relationship between the GPx1 Pro197Leu SNP 
and diseases including cancer, diabetes and vascular disease (Table 2-2). 
46 
2.3.6.1 Breast Cancer 
Hu and Diamond' e examined the GPx1 SNP in African American women, 79 with 
confirmed breast cancer and 517 controls. They found a greater incidence of the 
Leu/Leu genotype in women with breast cancer (23%) compared to the control group 
(12%) (OR 1.9, 95% CI 1.02-3.58). This study also examined whether the specific 
alleles affected the function of GNI using the human breast carcinoma cell line MCF-
7. The Leu allele was less responsive to an increase in selenium, indicating that this 
genotype has less GPx activity and presents an increased risk of breast cancer. 182 A 
larger study involving 372 cases and 399 controls that also took into account the female 
menopausal state found no relationship between breast cancer and the GPx1 SNP. 134 
This finding was supported by two of the largest studies both involving above 3,000 
subjects. 183 ' 184 The females in both studies were almoseall ( 94%) Caucasian, 
suggesting that any association found may be race-dependent. In a study by Raven-
Haren et al.24 involving 754 women, of whom 377 were diagnosed with breast cancer, a 
slightly higher risk of breast cancer was reported for participants that carried the Leu 
allele compared with Pro/Pro genotype (OR 1.43, 95% CI 1.07-1.92, p=0.05). In 
addition, the Leu/Leu genotype was associated with an increased risk of breast cancer in 
a study that examined two SNPs, GPx1 Pro197Leu and SOD2 Alal6Val. An increased 
risk of breast cancer was only uncovered when both GPx1 Leu/Leu and SOD2 Ala/Ala 
genotypes were found in patients (OR 1.87, 95% CI 1.09-3.19) when compared with 
patients carrying both GPx1 Pro/Pro and SOD2 Val/Val genotypes. = In summary, 
three studies have reported that both the GPx1 Leu/Leu genotype and Leu allele are 
associated with an increased risk of breast cancer. 
47 
2.3.6.2 Other cancers 
Ratnasinghe et al. 185 reported that the incidence of lung cancer was increased by 80% in 
individuals with the GPx1 Pro197Leu SNP compared to patients with the Pro/Pro 
genotype. Furthermore, the incidence was 130% higher if the patient had the Leu/Leu 
genotype (OR 2.3, 95% CI 1.3-3.8). In a study that compared 213 Japanese bladder 
cancer patients with 209 healthy native Japanese controls, the authors reported an 
increased incidence of bladder cancer, especially high grade tumours, if the patient had 
the Pro/Leu genotype compared to Pro/Pro genotype (OR 2.58, 95% CI 1.07-6.18). 137 
There were no patients or controls with the Leu/Leu genotype present in this Japanese 
population group. Two other studies report conflicting results, concluding that the Leu 
allele was associated with reduced risk of lung cancer. 186 ' 187 Rosenberger et al. 187 
examined individuals between the ages of 24-50 and found that the Leu allele played a 
protective role against lung cancer within this age group (OR 0.6, 95% CI 0.4-0.8). The 
larger study, with 1,230 participants and 432 patients with lung cancer, also reported 
that the Leu allele was associated with a lower risk of lung cancer among a younger age 
group (50-60 years) (OR 0.35, 95% CI 0.15-0.82). In addition, this study reported a 
non-significant trend in older age groups with the Leu allele towards a reduced risk of 
lung cancer. 186 The Leu allele was significantly associated with the risk of developing 
non-Hodgkin lymphoma in a study that involved 928 patients and 1,446 controls from 
the UK and USA (OR 1.25, 95% CI 1.05-1.48). 15° Finally, there have been two studies 
that reported no association with the GPx1 Pro197Leu SNP when investigating prostate 
cancer in smokers and survival after treatment for acute myeloid leukaemia. 120,172 
48 
2.3.6.3 Diabetes and Other Diseases 
A study involving 184 12DM Japanese patients investigated the relationships between 
the GPx1 Pro19'7Leu SNP genotypes and degree of macrovascular disease. 37 They 
reported that crmT and other measures of macrovascular disease were significantly 
greater in patients with the Pro/Leu compared to those with the Pro/Pro genotype 
(P9.003, n=33 and 151, respectively). Peripheral vascular disease was also found to be 
higher in individuals with the Pro/Leu genotype than those with the Pro/Pro genotype 
(p=0.027, n=5 and 7, respectively). 37 A similar study examined the coronary artery 
calcium score in 91 12DM patients and also found that the Pro/Leu genotype frequency 
was significantly higher in patients with scores higher than 1000 HU, (OR 3.61, CI 
0.97-13.42). 154 A study involving 180 11DM patients reported a higher frequency of the 
Pro/Leu genotype and less Pro/Pro in the 86 patients diagnosed with diabetic 
polyneuropathy compared to 94 patients without polyneuropathy, although the 
difference in the frequencies was not statistically significant. 38 The same group also 
reported in a study involving 466 patients with 11DM, found that the frequencies of 
GPx1 genotypes between those with and without diabetic neuropathy were not 
significantly different.76 It should be noted that the studies that examined diabetic 
neuropathy did not include a healthy (non-diabetic) control group. Sergeeva et al. 188 also 
compared the GPx1 SNP in 12DM patients who had sustained a myocardial infarction 
or stroke and found no genotype differences between the two groups and they were not 
different from control (non-diabetic) participants. 
Finally, Forsberg et al. 189 also compared the genotype of stroke patients with healthy 
controls, and found no association. In addition, none of the ten SNPs present in 
numerous antioxidants, including GPx1 Pro197Leu, were associated with GPx1 
genotype and the occurrence of brain tumours. 96 
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2.3.6.4 Summary 
Genotypes of the GPx1 Pro197Leu SNP have been associated with an increased risk of 
various diseases. The GPx1 Pro/Leu genotype has been linked to lung cancer, bladder 
cancer and complications in T2DM. The Leu allele and Leu/Leu genotype have been 
shown to increase the risk of breast cancer. Studies that have investigated the potential 
association of the GPx1 Pro197Leu SNP genotypes and diabetes, stroke, brain tumours 
and prostrate cancer are inconclusive. 
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Table 2-2: Studies investigating the relationships between genotypes of the GPx1 Pro197Leu SNP and disease 
Condition Reference Participants Cases /Controls 
Genotype 
Pro/Pro 
Cases a [%]/ 
Controls n f°/01 
Pro/Leu 
Cases n r/01/ 
Controls n i%1 
Leu/Leu 
Cases n [%]/ 
Controls n I%1 
Breast Cancer Cebrain et al. 2,271/2,280 Data not given Data not given Data not given 
2006' 84 (>94% Caucasians) 
Breast Cancer Cox et al lw 1,262/1,533 Data not given Data not given Data not given 
Breast Cancer Ahn et al.'" 1,0.38/1,088 472[45]/523 [48] 456[44]/453 [42] 110[11]/112[10] 
(>94% Caucasians) 
Breast Cancer Knight, et al. 134 372/399 192[48]/169[45] 171 [43]/164 [44] 34[9]/39[10] 
Breast Cancer Ravn-Haren, et 
al.74 
377/377 176[47]/205 [54] 168[44]/136[36] 33 [9]/36[10] 
Breast Cancer Hu et al.'" 79/517 36[46]/244[47] 25[32]/209[40] 18[23]/64[13] 
Prostate Cancer Choi, et al.' 724/1,474 249[49]/704[50] 213[421/578[41] 38 [7]/109[7] 
Lung Cancer Raaschou- 432/798 209[48]/348[44] 184[43]/358[45] 39[9]/92[11] 
Nielsen et al.'" 
Findings 
mi■ 
No significant association 
No significant association 
with GPx1 SNP on its own. 
However when stratified with 
another SNP in SOD2, the 
Leu/Leu genotype was 
associated with breast cancer 
(OR 1.87, 95% CI 1.09-3.19, 
p=0.03) 
No significant association. 
No significant association. 
Leu (T) allele associated 
with a slightly higher risk of 
breast cancer (OR 1.43, 95% Cl 
1.07-1.92, p=0.05) 
Leu/Leu genotype 
significantly higher in African 
American breast cancer patients 
(OR 1.9, 95% CI 1.02-3.58, 
p=0.045) 
No significant association. 
Leu allele was associated 
with a lower risk of lung cancer 
specifically among 50-60 years 
old (IRR 0.35, 95% CI 0.15- 
0.82, p=0.02) 
Condition Reference Participants Cases /Controls 
Genotype 
Pro/Pro 
Cases n 
Controls n [%1 
Pro/Leu 
Cases n 
Controls n [%1 
Leu/Leu 
Cases n I'VeJ/ 
Controls n 
Lung Cancer Ratnasinghe, et 
al.'" 
315/313 91[29]/132[42] 157[50]/I35[43] 67[21]/46[15] 
Lung Cancer Rosenberger et 
al. 187 
186/207 114 [61]/97[47] 63[34]/89[43] 9[5]/21[10] 
Bladder Cancer Ichimura, et 
al.'" 
213/209 
(Japanese) 
166[77]/187[89] 47[22]/22[10] 0[0]/0[0] 
Non-Hodgkin's 
lymphoma (NHL) 
Lightfoot, et 
al.'" 
928/1,446 453[49]/773[54] 387[42]/551[38] 81[9]/120[8] 
Acute Myeloid 
Leukaemia 
Koistinen, et 
al.'2°  
89 21[24] 39[44] 29[33] 
T1DM 
(diabetic neuropathy) 
Chistiakov, et 
al. 76 
216 (DN+) 
250 (DN-) 
151[701/167[67] 60[28]/77[31] 5 [2]/6 [2] 
T2DM Hamanishi, et 
al." 
Participants total 184 
(Japanese) 
151[82] 33[18] 0[0] 
Findings 
Leu allele genotype 
frequency higher in lung 
cancer (OR 2.3, 95% Cl 1.3- 
3.8, p<0.00I) 
Leu allele was reported in 
patients people below the age 
of 50 to have a protective role 
in the early onset of lung cancer 
(OR 0.6, 95% Cl 0.4- 
0.8,p=0.002) 
Pro/Leu genotype 
significantly associated with 
advanced tumour stare in 
Japanese bladder cancer 
patients (OR 2.58, 95% Cl 
1.07-6.18, p=0.034) 
A significant association 
between Leu allele and increase 
risk of NHL (OR 1.25, 95% CI 
1.05-1.48, p=0.01) 
No significant association. 
No significant association. 
Pro/Leu genotype 
associated with intima-media 
thickness in Japanese 
population (p=0.003, n=33/15 I 
respectively) 
Condition Reference Participants Cases /Controls 
Genotype 
Pro/Pro 
Cases n 
Controls n 1[%1 
Pro/Leu 
Cases n 
Controls n 
Leu/Leu 
Cases n MO/ 
Controls n I °41 
Findings 
T2DM 
(with and without 
complications) 
T1DM 
(diabetic 
polyneuropathy) 
T2DM 
(coronary artery 
calcium score) 
Sergeeva, et al. 188 
Zotova, et al.38 
Nemoto et al.' 54 
103/52 
53 MI cases 
50 Stroke cases 
86 (DNP+) 
94 (DNP-) 
91 
27[52] 
28[53] 
28[56] 
60 [70]/64 [67] 
71[78] 
19[37] 
21[40] 
20[40] 
24[28]/28[31] 
20[22] 
6[11] 
4[7] 
2[4] 
2[2]/2[2] 
Data not given 
No significant association. 
No significant association. 
Pro/Leu genotype had 
significant higher coronary 
artery calcium score than 
patients with Pro/Pro genotype 
(p=0.006) 
Brain Tumour 
Stroke 
Rajaraman, et 
al.96 
Forsberg, et 
al.' 89 
565/494 
101/214 
250[47]/236[51] 
56[53]/113[55] 
226[431/178[39] 
38[38]/85[38] 
52[10]/46[10] 
7[7]/16[7] 
No significant association. 
No significant association. 
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2.3.7 Catalase and SNPs 
The role of catalase is discussed in detail in section 1.2.4. A search of the NCBI 
database identified 245 catalase SNPs, with most of the studies focusing on the 
relationship between diseases in humans and rs1001179, a C>T substitution at position - 
262 from the transcription start site. This SNP is found within the GC-rich area of the 
promoter region and the mutation resides in the 5'-untranslated promoter sequence that 
increases expression, and has been correlated with blood catalase levels. 190-192 This 
SNP will be reviewed in depth in section 2.3.8, with details of published studies shown 
in Table 2-3. 
Ten other catalase SNPs have been identified in the exon regions and only one has been 
investigated in disease states. This silent mutation, rs769217, found in exon 9, changes 
T>C and leaves the amino acid at position 389 as aspartic acid (Asp). It has been shown 
to have no association with the prevalence of T1DM, 193 no evidence of increased 
susceptibility to systemic lupus erythematosus (SLE) 194 and no association with non-
pathological cognitive ageing. 175 This SNP was also studied in relation to breast cancer 
along with over 50 other SNPs, including three other catalase SNPs, rs511895, 
rs7104301 and rs1049982. It was, however, reported that specific SNPs found in the 
antioxidant enzyme, thioredoxin, were associated with an increased risk of breast 
cancer. 195 
Another thirteen catalase SNPs present in the promoter region of the gene have been 
identified, of which three have been studied in relation to disease. The SNPs are: rs 
7943316, an A>T substitution at position -21 (A-211); rs769214, an A>G substitution 
at position -844 (A-844G); and rs1001179, a C>T SNP at position -262 (C-262T). The 
A-21T SNP is not associated with either 11DM or T2DM. 126 One study examined the 
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association between all three silent SNPs along with another 45 SNPs and the 
occurrence of post cardiac surgery myocardial infarction.'  SNP genotypes 
appeared to protect against postoperative myocardial infarction. As the C-262T SNP has 
been the most frequently investigated in disease states, it will be discussed in more 
detail (see Appendix A5.3. for a link to catalase SNPs). 
2.3.8 Catalase C-262T and Disease 
There have been eighteen studies that have investigated the catalase SNP C-262T in 
relation to disease (Table 2-3). 
2.3.8.1 Breast Cancer 
An increased risk of breast cancer has been linked to the catalase C-262T SNP in a 
number of case-control studies. A large study investigated 2,088 women of whom 1,017 
were diagnosed with breast cancer. The authors found that women carrying the C/C 
genotype and who consumed more that 10 pieces of fruit per week had a reduced risk of 
breast cancer compared with those than had the C/T or T/T genotype (OR 0.59, 95% CI 
0.38-0.89). This study also reported that women with C/C genotype had higher catalase 
red blood cell activity. 197 Another study conducted by the same group in 446 breast 
cancer patients found that there was no association with this catalase SNP and the 
development of radiotoxicity from treatment. 165 A smaller study in 279 breast cancer 
patients after either radiation therapy and/or chemotherapy found that the T/T genotype 
was weakly associated with a reduced risk of death in women that had received cancer 
treatment: this was not statistically significant (p=0.150). 166 The two largest studies, in 
which over 50 SNPs were examined, including catalase C-262T, found no associations 
with breast cancer risk when the SNPs were examined alone.'" 195 However, one study 
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reported an association between C-262T and breast cancer when a two-way analysis 
was performed that included another catalase SNP, rs511895 (p.0085). 198 
2.3.8.2 Other Cancers 
Three studies examining non-Hodgkin lymphoma, lung cancer and survival in acute 
myeloid leukaemia found no association with the C-262T catalase genotype. 75 ' 120'  150 
However, when investigating the relationship with prostate cancer, it was noted that in 
patients diagnosed under 65 years of age, the T/T genotype was weakly associated with 
an increased risk (OR 2.0, 95% CI 0.97-3.95). 172 
2.3.8.3 Diabetes 
Three studies have investigated the relationship between T1DM and catalase C-262T 
SNP genotypes. 38 ' 76 ' 193 The largest of the three studies involved two separate groups: 
one consisting of 1,642 individuals from large families, and the second, a large case-
control study involving 7,460 participants of which 3,530 had T1DM. No association 
between catalase C-262T genotypes and the risk of T1DM was found. I93 In contrast to 
these findings, the other two studies (466 and 180 patients, respectively) reported that 
Ti DM patients with the catalase C allele had an increased risk of developing diabetic 
neuropathy.38' 76 
2.3.8.4 Other Diseases 
A case-control study involving 100 patients diagnosed with hypertension and 93 
normotensive subjects investigated the relationship between blood pressure and two 
SNPs within the promoter region of the catalase gene, C-262T and A-844G. There was 
a significant association between hypertension and the catalase genotype combination - 
844 A/A and -262 C/T and T/T. I98 A study investigating the risk of asthma in 
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association with catalase C-262T SNP, involved 567 participants, of whom 251 had 
asthma, reported that the C allele frequency was significantly higher in patients 
compared with controls (p0.033). It was also found that non-smokers carrying the T 
allele were protected against the development of asthma (OR 0.35, 95% CI 0.15-
0.85))48 A later study performed by the same group found that there was no association 
between catalase genotype and chronic obstructive pulmonary disease. 139 A case-control 
study involving 267 participants, of which 137 had been diagnosed with Alzheimer's 
disease, reported no association with the C-262T polymorphism. 199 There have also 
been no associations found between the catalase genotype and the autoimmune disease, 
systemic lupus erythematosus, 194 or acute renal failure." 
2.3.8.5 Summary 
A small number of studies have shown equivocal results when investigating the 
associations between genotypes from the catalase C-262T SNP and disease in humans. 
The T allele in the catalase C-262T SNP has been reported to protect against the 
development of asthma, and the development of diabetic nephropathy in T1DM 
patients. In contrast, the C/C genotype was found to be associated with a reduced risk of 
developing breast cancer. However, other studies have reported that individuals with the 
T/T genotype have an increased risk of hypertension and prostate cancer. The remainder 
of the studies (67%) reported no association between disease and the catalase C-262T 
SNP. 
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0.59, 95% Cl 0.38-0.89, 
p=0.02) 
No significant association. 
No significant association. 
However TI' genotype was 
slightly associated with 
decreased hazard of death 
(p=0.150). 
T/T genotype associated 
with an increased risk in men 
diagnosed with prostate cancer 
before the age of 65 (OR 2.0, 
95% Cl 0.97-3.95, p=0.079) 
No significant association. 
No significant association. 
No significant association. 
No significant association. 
Table 2-3: Studies investigating the relationships between genotypes of the catalase C-262T SNP and disease 
Participants Genotype 
Condition Reference CC CT TT Findings Cases/Controls Cases n r/oF Cases n [%]/ Cases n t%]/ 
Controls n Controls n [%1 Controls n i%1 
Breast Cancer Cebrain et. al. 4,474/4,580 Data not given Data not given Data not given No significant association 
2006 184 
Breast Cancer Oestergaard et. al. 2,271/2,280 Data not given Data not given Data not given No significant association 
2006' 95 
Breast Cancer Ahn, et al. 197 1,008/1,056 614[61]/679[64] 349[35]/335[32] 45[5]/42[4] C/C genotype showed a 
reduced risk of breast cancer 
in women that consumed >10 
pieces of fruit per week (OR 
Breast Cancer Ahn, et al 165 446 233[56] 162[39] 22[5] 
Breast Cancer Ambrosone, et 
ai. 166 
279 171[62] 93[33] 15[5] 
Prostrate Cancer Choi, et al."2 724/1,474 317[62]/885[63] 165[32]/461[32] 26[5]/57[4] 
Lung Cancer Ho, et al. 25 240/240 209[90]1217[ 91] 19[10]/23[ 8] 0[0]/2[ 1] 
Non-Hodgkin 
lymphoma (NHL) 
Lightfoot, et al. 15° 928/1,446 554[61]/867[60] 298[33]/498[35] 57[6]/72[5] 
Acute Myeloid Koistinen, et al.' 29 89 38[43] 39[44] 12[13] 
Leukaemia 
T1DM Pask, et a1. 193 3,530/3,930 2,189[62]/2,397[61] 1,165[33]/1,376[35] 176[5]/157[5] 
As well as 
in large families 1,642 985[60]/1,018[62] 575[35]/542[33] 82[5]/82[5] 
Ui 
00 
Condition 
Participants Genotype 
Reference 
Cases/Controls 
CC 
Cases n [%]/ 
Controls n [°/0] 
CT 
Cases n [%]/ 
Controls n F°A1 
TT 
Cases n I°A1/ 
Controls n [%1 
T1DM Chistiakov, et al. 76 216 (DN+) 83[38]/80[32] 80[37]/74[30] 53[25]/96[38] 
(diabetic 
neuropathy) 
250 (DN-) 
T1DM Zotova, et al. 38 86 (DPN+) 56[65]/50[53] ' 26[30]/42[45] 4[5]/2[2] 
(diabetic 
neuropathy) 
94 (DPN-) 
Asthma Mak, et al. 148 251/316 237[95]/279[91] 12[5]/29[9] CT and TT 
Data pooled 
Chronic Mak et al: 39 165/165 149[91]/153[93] 13[8]/11[7] 2[1]/0[0] 
Obstructive 
Pulmonary Disease 
Hypertension Zhou, et al. 198 220/191 6[5]/2[1] 34[30]/37[28] 86[68]/91[72] 
Alzheimer's Goulas, et al. 199 137/130 84[61]/74[57] 44[32]/49[38] 9[9]/7[7] 
Disease 
Systemic Lupus D'Souza, et al. 194 100/113 97[87]/102[91] 14[13]/10[9] 0[0]/0[0] 
Erythematosus 
(SLE) 
Acute Renal Perianayagam, et 200 112[56] 74[37] 14[7] 
Failure 
Findings 
T allele shown to protect 
against the development of 
diabetic neuropathy (OR 1.98, 
95% Cl 1.53-2.58,1)=0.002) 
T allele showed a reduced 
risk of diabetic neuropathy 
(OR 1.6, 95% CI 1.06-2.42, 
p=0.027) 
T allele was found to 
protect against asthma in non - 
smokers 
No significant association. 
C/T and T/T genotype 
showed an association with 
hypertension when patients had 
another SNP present 
No significant association. 
No significant association. 
No significant association. 
2.3.9 Conclusions 
There is weak evidence that the most investigated SNPs of the SOD2, GPx1 and catalase 
genes have been associated with a number of diseases. The SOD2 Alal6Val SNP has been 
linked with cancer, in 51% of all studies investigated (67% for breast cancer) and the 
Ala/Ala genotype or Ala allele are particularly indicative of this relationship. The same 
genotypes have also been associated with an increased risk of motor neurone disease, brain 
tumours, systemic sclerosis and schizophrenic subjects developing tardive dyskinesia 
during antipsychotic therapy. The Val/Val or Val allele has been positivity associated with 
CVD risk and with co-morbidities in 57% of studies in 11DM and T2DM patients. The 
GPx1 Pro197Leu SNP provides the genotype Leu/Leu or Leu allele and has been associated 
with breast cancer in 50% of studies. However, with other cancers, the results are 
inconclusive, with only 29% of studies showing that the Leu allele plays a protective role 
against cancer, 29% showing that there is an increased risk of cancers and 29% of studies 
showing no association with GPx1 genotype. The catalase C-262T SNP was reported to be 
associated with the reduced risk of breast cancer in patients with the C/C genotype, and in 
80% of studies, to have no association with breast cancer. With other cancers, only one 
study found an association between the T/T genotype and prostate cancer and the rest found 
no association. In 11DM, there were 4,176 cases examined and in only 15% of these cases 
was there an association found with the T allele. The T allele genotype has also been linked 
to asthma and hypertension. In summary, this review has demonstrated, at best, weak 
evidence that specific diseases are linked to selected SNPs of SOD2, GPx1 and catalase 
genes. However, to the best of our knowledge, there have been no studies examining CICD 
with any of the three antioxidant enzyme SNPs. Hence, the overall aim of the present study 
is to examine a CICD population and determine any specific genotypes have any affect on 
the aetiology CICD. 
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2.3.10 Aims of this study 
Variations in antioxidant enzyme activities may be the result of polymorphisms present 
in the genes regulating these antioxidants in CKD patients. Therefore, the aims of the 
present study were to determine whether: 
(a) the frequency of specific SNPs, present in GPxl, SOD2 and catalase genes and 
whether antioxidant enzyme activities are significantly different between CKD 
patients (n=230) and control subjects (n=224), 
(b) there are associations between antioxidant genotypes and renal function. 
Additionally, a cohort study was employed to determine whether the progression of 
kidney disease (i.e., decline in eGFR) over approximately one year was associated: 
(c) with specific genotypes resulting from the aforementioned GPxl, SOD2 and/or 
catalase SNPs, and 
(d) altered plasma GPx, RBC GPx, RBC SOD and/or RBC catalase activities. 
Chapter 3 describes and discusses the results obtained from the case-control study 
(Research Aims a and b). 
Chapter 4 describes and discusses the results obtained from the cohort study (Research 
Aims c and d). 
Chapter 5 provides a general discussion and provides suggestions for future research. 
There is some repetition as chapters 2, 3 and 4 were written for publication in various 
peer reviewed journals. 
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CHAPTER 3: ANTIOXIDANT GENOTYPE AND ACTIVITY 
IN RELATION TO KIDNEY FUNCTION: A 
CASE-CONTROL STUDY 
3.1 Abstract 
Background and Objectives: Oxidative stress is associated with the progression of 
chronic kidney disease (CKD). Single nucleotide polymorphisms (SNPs) of the 
antioxidant enzymes superoxide dismutase (SOD)2 Alal6Val, glutathione peroxidase 
(GPx)1 Pro 197Leu and catalase C-262T have been associated with the pathogenesis of 
cancer and diabetes. However, links between SNPs of these enzymes and CKD have yet 
to be investigated. The aims of this study were to compare antioxidant genotypes and 
activities of CKD patients and controls, and to determine their relationship to kidney 
function. Methods: CKD patients (n=230) and controls (n=224) were screened for the 
SNPs, GPxl, SOD2 and catalase. In addition, plasma and RBC GPx, RBC SOD and 
RBC catalase activities were measured. Results: Significantly more CKD patients (n=5) 
had the GPx1 Leu/Leu genotype compared to controls (n=0). Although not significant, 
patients with the GPx1 Leu/Leu or SOD2 Ala/Ala genotypes had reduced eGFR 
compared with the GPx1 Pro/Leu and SOD2 Val/Val genotypes. CKD patients had 
significantly lower plasma GPx and RBC catalase activities compared to controls. In 
contrast, both RBC GPx and RBC SOD activities were significantly higher in CKD 
patients (p<0.001). Conclusion: CKD is associated with impaired plasma GPx and 
catalase activities and enhanced RBC GPx and SOD activities. While genotype 
frequencies were similar for both groups, lower eGFR was associated with the GPx1 
Leu/Leu genotype. 
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3.2 Introduction 
Variations in antioxidant enzyme activities of GPx, SOD and catalase may be the result 
of polymorphisms present in the genes regulating antioxidants in CKD patients. 
Therefore, the aims of the present study were to determine whether: (a) the frequency of 
specific SNPs, present in GPx1 Pro197Leu, SOD2 Alal6Val and catalase C-262T genes 
and antioxidant activities are significantly different between CKD patients and control 
subjects, and (b) there is an association between antioxidant genotypes and CKD. 
3.3 Methods 
3.3.1 Study Subjects 
The study was approved by the Human Research Ethics Committee (Tasmania) 
Network (H08618). A total of 269 CKD patients were recruited in Tasmania, Australia, 
(population —0.5 million), this included greater than 90% of the Northern Tasmania's 
diagnosed CKD population (physicians estimate) between March 2006 and May 2008, 
from the Launceston General Hospital, private clinical practices in the Launceston area, 
and the North West Satellite Renal Unit (Burnie). Of the patients initially recruited and 
who provided written consent, 39 did not provide a blood sample; hence, data from 230 
were included in this study. Inclusion criteria for the CKD subjects were? 18 years of 
age, diagnosed with CKD using the modification of diet in renal disease (MDRD) 
formula to estimate glomerular filtration rate (eGFR) <60mL/min/1.73m 2. The primary 
causes of CKD, according to the classification system used by the Australian and New 
Zealand Dialysis Transplant Registry, 200  were vascular disease (n=77), 
glomerulonephritis (n=43), diabetic nephropathy (type 1, n=9; type 2, n=40), reflux 
nephropathy (n=11), polycystic kidney disease (n=7), analgesic nephropathy (n=2), 
other (n=36) and uncertain diagnosis (n=5). Control subjects were recruited from the 
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general population in North and North West Tasmania and through the Australian 
Electoral Commission roll. Letters were mailed to over 2,000 individuals. 
Approximately 500 people provided written consent to take part in the study with 41 
reporting they had a prior diagnosis of kidney disease. The 459 participants that were 
left they were age and sex matched to the CKD patients as closely as possible as they 
responded, leaving 224 participants for inclusion into this study as general population 
controls. Inclusion criteria for the control subjects were no known history of kidney 
disease or impairment. Some control subjects had existing high blood pressure (n=70), 
T2DM (n=13), angina or other cardiac conditions (n=33). The control participants were 
grouped by age and gender to match the CKD patients as closely as possible. However, 
the study was limited by the difficultly of recruiting controls >80 years, which resulted 
in a significant difference in the mean ages of the two groups. 
3.3.2 Blood Sampling and Biochemical Analysis 
Venous blood, collected in anticoagulant-free and lithium heparin tubes, was 
centrifuged, serum and plasma separated, and stored at -80 °C for later analysis of serum 
creatinine and plasma GPx activity. RBC lysate was prepared from lithium heparin 
samples that were washed with 0.9% saline and lysed with cold distilled H20 and stored 
at -80°C for measurement of RBC GPx, SOD and catalase activities.201 Both plasma and 
RBC GPx activities were measured on a DataPro Clinical Analyzer (Thermo-Electron 
Corporation Melbourne, Australia), RBC SOD and catalase activities measured on a 
Cobas Mira Clinical Analyzer (Roche Laboratories, USA). Commercially available kits 
(Ransel, Randox Laboratories Ltd, Crumlin, Ireland) were used to measure plasma, 
RBC GPx and RBC SOD activities. The inter- and intra-batch coefficients of variation 
(CV) were: plasma GPx 6% and 10.2%; RBC GPx activity, 5.2% and 6.7%, and SOD 
activity 4.6% and 5.7%, respectively. RBC catalase activity was measured using 
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Slaughter and co- workers202 methodology and inter- and intra-batch CV's were 1.8% 
and 5.3%, respectively. 
Serum creatinine was measured using an Architect C8000 biochemical analyser (Abbott 
Diagnostics, Abbott Park, USA, Calibrator MC Cal Traceable to NIST SRM 909b-2), 
within 3 months of blood collection, and used to calculate eGFR by the MDRD 
equation. 
3.3.3 Genotyping Method 
Genomic DNA was isolated from whole blood within two weeks of blood collection 
using a Viogene Blood and Tissue Genomic DNA Extraction Miniprep System 
(Diagnostic Technology, Belrose, Australia). GPx1 Pro197Leu and 50D2 Alal6Val 
SNPs were determined using a RFLP-PCR assay and catalase C-262T SNP was 
determined through sequencing by Australian Genome Research Facility Ltd (AGRF), 
3.3.3.1 Glutathione Peroxidase 
The GPx1 Pro197Leu SNP was genotyped using an RFLP-PCR assay based on the 
methods from Forsberg, et al. 203 Primers were designed to produce a 460bp amplicon 
containing the SNP site, using the NM 000581 sequence from NCIB and Primer3. PCR 
primers synthesized by Geneworks (Adelaide, Australia). DNA was amplified using 
Qiagen Hotstar Taq MasterMix (Qiagen, Australia) and 0.25 uM of each primer in a 10 
uL volume on a PTC-200 (MJ Research) with the initial temperature at 94 °C for 15 
minutes, then 94°C for 45 s, then 56°C for 45 s, then 72 °C for 30 s repeated 34 times 
and then 72°C for 10minutes (Table 3-1). Ten units of Apal which cuts at the sequence 
GGGCCC site was added directly to the PCR mix followed by incubation at 37 °C for 60 
min. Digestion fragments were visualized by electrophoresis in a 3% agarose gel in 
TBE buffer (see Appendix 1). Expected fragment sizes are as follows: 
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• homozygous prolime/proline- 252, 120, and 88bp, 
• heterozygous proline /leucine —252, 208, 120, 88bp, and 
• homozygous leucine/leucine — 252 and 208bp 
Each PCR assay included a NTC, homozygous proline/proline and homozygous 
leucine/leucine DNA sample as positive controls. Also 10% of the samples were 
sequenced to ensure the accuracy of the genotyping. 
3.3.3.2 Superoxide Dismutase 
The SOD2 Alal6Val was genotyped using an RFLP-PCR assay based on the method of 
Li, et al. 112 Primers were designed to produce a 492bp ainplicon containing the SNP 
site, using the NM 001024466 sequence from NCBI Genebank and Primer3 112 . PCR 
primers weresynthesized by GeneworIcs (Adelaide, Australia) (Table 3-1). The isolated 
DNA was amplified using Qiagen Hotstar Taq MasterMix (Qiagen, Australia) 
incorportating the 'Q solution' at IX concentration in the final reaction mix according to 
manufacturers instructions and 0.25 uM of each primer in a 10 uL volume on a PTC-
200 (MJ Research) with the initial temperature at 94°C for 15 minutes, then 94°C for 45 
s, then 56°C for 45 s, then 72°C for 30 s repeated 34 times and then 72 °C for 10minutes. 
Ten units of BsaWI which cuts at the sequence WCCGGW (where W = A/T) site was 
added directly to the PCR mix followed by incubation at 60 °C for 60 min. Digestion 
fragments were visualized by electrophoresis in a 2% agarose gel in TBE buffer (see 
Appendix 1). Expected fragment sizes are as follows: 
• homozygous alanine/alanine- 492 bp, 
• heterozygous alanine/valine — 492, 339 and 153 bp, and 
• homozygous valine/valine —339 and 153 bp 
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Each PCR assay included a NTC, homozygous alanine/alanine and homozygous 
valine/valine DNA sample. Also 10% of the samples were sequenced to ensure the 
accuracy of the genotyping. 
3.3.3.3 Catalase 
The catalase SNP C-262T, the genotype was carried out be sequencing a 260bp 
fragment. The PCR primers were designed by Forsberg, et al. 191 and were synthesized 
by Geneworlcs (Adelaide, Australia). DNA was amplified using Qiagen Hotstar Taq 
MasterMix (Qiagen, Australia) and 0.25uM of each primer in a lOuL volume on a TC-
200 (MJ Research) with the initial temperature at 94 °C for 15 minutes, then 94°C for 
30s, then 55°C for 30 s, then 72°C for 30 s repeated 35 times (Table 3-1). The PCR 
product was diluted one in two, sequencing carried out by Australian Genome Research 
Facility Ltd (AGRF), with the reverse primer (See Appendix 1 for sequencing) 
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Table 3-1: Methodology for determining antioxidant SNPs 
SNP 
	
Primers 	 PCR Protocol 
GPx1 Pro197Leu F=5'-CGCCAAGAACGAAGAGATTC-3' Denature: 94 °C for 15 mins 
R=5'-CAGGTGTTCCTCCCTCGTAG-3' followed by 94 °C for 45 s 
Annealing: 56°C for 45 s 
Extension: 72°C for 30 s 
#Cycles:30 
SOD2 Ala16Val F=5'-CACCAGCACTAGCAGCATGT-3' Denature: 94 °C for 15 mins 
R=5'-GGTGACGTTCAGGTTGTTCA-3' followed by 94°Cfor 30 s 
Annealing: 56°C for 30 s 
Extension: 72°C for 30 s 
#Cycles: 37 
Catalase C-262T F=5'-TGAAGGATGCTGATAACC-3' 	Denature: 94°C for 15 mins 
R=5'-ATCAGCACCACCCCCTCGTC-3' followed by 94°C for 30 s 
Annealing: 55 °C for 30 s 
Extension: 72°C for 30 s 
#Cycles: 35 
N/A 
Restriction Digest 
Apal incubates at 37°C for 60 mins 
Pro/Pro-252, 120 and 88 bp 
Pro/Leu-252, 208, 120, 88 bp 
Leu/Leu-252 and 208 bp 
BsaWI incubation at 60°C 60 min 
Ala/Ala-492 bp, 
Ala/Val-492, 339 and 153 bp 
Val/Val-339 and 153 bp 
F = forward primer; R = reverse primer 
3.3.4 Statistical Analysis 
Hardy-Weinberg analysis was performed on all three genotype population groups. 
SOD2 and catalase genotypes for both controls and patients were within the Hardy-
Weinberg equilibrium. However, deviation from the Hardy-Weinberg equilibrium was 
observed in GPx1 genotypes for both patients and controls; both having reduced 
Leu/Leu genotypes and higher Pro/Leu genotypes. Therefore, the comparison of patient 
and control genotype frequencies were analysed using the Chi squared test. Sample size 
calculations predicted a minimum requirement of 239 patients and 239 controls (refer 
Appendix 2). 189 
The associations between outcome measures, primary exposure measures and other 
covariates were estimated using general linear modelling (GLM). Ordinal logistic 
regression was used as a non-parametric alternative to GLM, when skewness and 
heteroskedasticity of residuals indicated that assumptions of simple linear regression 
were violated, and comparisons reported as odds ratio (OR) with all analysis being 
adjusted for age. .Selection of covariates to include in the multivariate models was 
performed using backward stepwise regression with P-value criteria being 0.1. When 
determining associations with either eGFR or antioxidant enzyme activities in patients 
and controls separately, the age, gender, smoking status, all antioxidant activities, 
antioxidant genotypes, primary causes of CKD (patients), co-morbidities (controls) and 
medications were examined. P-values were corrected for multiple comparisons using 
the Holm method. Whilst R2 values would have assisted in testing 'goodness of fit' to 
the regression model, these were all <0.1, and hence, deemed irrelevant and not 
included All statistical analyses were performed using Stata 10.1/IC (StataCorp LP, 
College Station, TX, USA). 
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3.4 Results 
The demographics of CKD patients and controls are presented in Table 3-2. There were 
no significant differences between patients and controls in gender distribution or 
smoking status. Patients were significantly (P<0.001) older than controls, and hence, all 
analyses were adjusted for age. Although, antioxidant activities were not influenced by 
age in CKD patients, age was associated with reduced plasma GPx in controls (OR 
0.71, 95% CI 0.51 to 0.97, p=0.034). Interestingly, when the controls were stratified 
according to eGFR (and stages of CK13), 13% were found to be in stage 3 according to 
Kidney Disease Outcomes Initiative (KDOQI) guidelines6 (Table 3-2). 
Table 3-2: Demographics and clinical characteristics of CKD patients and controls 
Controls (n=224) C1CD patients (11=230) 
Gender, Female/Male 
Age, mean±SD (range) 
Smoking Status, n (%) 
111/113 
63.6±10.7 (27-85) 
106/124 
68.6±12.9 (24-92)* 
Never Smoked 107 (48%) 80 (35%) 
Given up 85 (38%) 53 (23%) 
Current Smoker 15 (7%) 10(4%) 
Stages of CKD, n (%) 
Stage 1 (>90m1/min/1.73m 2) 28 (13%) 0(0%) 
Stage 2 (89-60m1/min/1.73m 2) 166 (74%) 9(4%) 
Stage 3 (59-30m1/min/1.73m 2) 30 (13%) 104 (45%) 
Stage 4 (29-15m1/min/1.73m 2) 0(0%) 91(40%) 
Stage 5 (<15m1/min/1.73m 2) 0(0%) 26 (11%) 
Medications, n (%) 
Erythropoietin 0(0%) 115 (50%) 
ACE inhibitor 36 (16%) 104 (45%) 
Angiotensin receptor blocker 29 (13%) 74 (32%) 
Statin 41(18%) 83 (36%) 
Anti-inflammatory 7(3%) 17 (7%) 
Significant difference in mean age was estimated by general linear modelling. sp<0.001 
Antioxidant enzyme genotype frequencies for CKD patients and controls are shown in 
Table 3-3. Significantly (p=0.023) more patients had the GPx1 Leu/Leu genotype 
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compared to controls (5 vs 0), with the primary cause of CKD being diabetes for all five 
patients (T1DM, n=1; T2DM, n=4) and four patients in stage 4 of CKD. However, the 
precise odds ratio for this comparison could not be determined due to the zero count in the 
controls. There were no other statistically significant differences in genotype frequencies 
between patients and controls. 
Table 3-3: Genotype frequency and the odds ratio (OR) for differences in genotypes 
between CKD patients and controls 
Controls 
n=224 
CKD 
patients 
n=230 OR (95`)/0C1) 
GPx Pro197Leu 
Pro/Pro 112 (50%) 110 (48%) 0.92 (0.62-1.35) 
Pro/Leu 112 (50%) 115 (50%) 1.0 (0.68-1.50) 
Leu/Leu 0 5 (2%) 00 (1.23-00)* 
SOD2 Alal6Val 
Ala/Ala 55 (25%) 54 (23%) 0.94 (0.60-1.48) 
Ala/Val 119(53%) 116(51%) 0.90(0.61-1.32) 
Val/Val 50 (24%) 60 (26%) 1.23 (0.78-1.94) 
Catalase C-262T 
C/C 138 (62%) 148 (64%) 0.77 (0.52-1.15) 
C/T 73 (33%) 74 (32%) 0.94 (0.62-1.42) 
T/T 13 (5%) 8 (4%) 1.62 (0.61-4.59) 
Due to skewness and heteroskedasticity, the odds ratio (OR) and 95% confidence intervals 
(95%CI) were estimated using ordinal logistic regression and adjusted for age,*p=0.027. 
The precise estimate 95% Cl cannot be determined due to the zero count in the controls 
with Leu/Leu genotype. 
00 = infmity. 
As expected, eGFR was significantly (p<0.001) lower in patients than in the control group 
and this was consistent across the three-antioxidant genotypes (Table 3-4). There was a 
trend towards reduced eGFR in patients with the Leu/Leu GPx1 genotype when compared 
to patients with the Pro/Leu genotype (p=0.031) and eGFR was non-significantly lower in 
patients with the SOD2 Ala/Ala genotype compared with the VaVVal genotype 
(p=0.074). In addition, controls with the catalase C/T genotype had significantly lower 
eGFR compared to controls with the catalase T/T genotype (p=0.028) (Table 3-4). 
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Table 3-4: Comparison of eGFR according to antioxidant genotypes, in both CKD patients and controls 
separately. Additional comparisons were also made within the same genotype and with those that were 
statistically significant or approaching significance are reported below. 
Controls (n=224) 
Mean±SD 	OR (95% CI) 
CKD patients (n=230) 
Mean±SD 	OR (95% CI) 
All (eGFR ml/min/1.73m 2) 73.15±13.34 31.00±14.31 0.01(0.002 -0.009)** 
Genotypes 
GPx1 Pro197Leu 
Pro/Pro 	 73.53±12.56 Ref 30.67±14.84 Ref 
Pro/Leu 72.77±14.11 1.25 (0.79-2.00) 31.60±14.05 1.17 (0.72-1.92) 
Leu/Leu 24.40±5.31 0.63 (0.82-1.25) a 
SOD2 Alal6Val 
Ala/Ala 	 73.89±14.70 Ref 28.85±13.62 Ref 
Ala/Val 72.84±13.06 1.17 (0.59-2.36) 30.75±14.16 1.27 (0.74-2.14) 
Val/Val 	 73.08±12.64 0.95 (0.53-1.70) 33.41+15.06 1.82 (0.94-3.49)b 
Catalase C-262T 
C/C 	 73.20±13.36 Ref 31.45±14.07 Ref 
C/T 71.89±13.14 1.25 (0.75-206) * 31.51±15.09 0.80 (0.48-1.36) 
T/T 	 79.77±13.17 2.42 (0.87-6.72) 27.25±11.90 0.59 (0.21-1.65) 
Mean eGFR in CKD patients compared with controls. The odds ratio (OR) and 95% confidence interval (95%CI) 
were estimated using ordinal logistic regression due to skewness and heteroskedasticity and adjusted for age. 
** p<0.0001; * p=0.028 (OR 3.02, 95% CI 1.04 to 8.74) catalase C/T compared with T/T in controls; 
a p=0.054 (OR 0.53, 95% CI 0.28 to 0.101) GPx1 Pro/Leu compared with Leu/Leu in CKD patients; 
b p=0.074 (OR 1.82, 95% CI 0.94 to 3.49) SOD2 Ala/Ala compared with ValNal in CKD patients. 
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Figure 3-1 A shows that CKD patients had significantly lower plasma GPx (OR 0.04, 
95% Cl 0.03 to 0.07) and catalase (OR 0.48, 95% CI 0.34 to 0.67; Figure 3-1 D) 
enzyme activities compared to controls. In contrast, both RBC GPx and SOD enzyme 
activities were significantly higher in patients than in controls (OR 2.77, 95% CI 1.96 to 
3.9; OR 2.71 95% CI 1.91 to 3.84, respectively) (Figure 3-1 B, C). 
Figure 3-1: Antioxidant enzyme activities in CICD patients and controls. 
(A) plasma GPx, (B) RBC GPx, (C) RBC SOD and (D) RBC catalase. Data analysed using general linear 
modelling and logistic regression and adjusted for age, * p<0.0001. Error bars show standard deviation. 
The relationships between eGFR and antioxidant enzyme activities in patients and 
controls determined using univariate analysis are shown in Figure 3-2 A. There was a 
significant correlation between eGFR and plasma GPx activity in CKD patients (OR 
4.29, 95% CI 2.52 to 7.31, p<0.0001) and this relationship persisted in multivariate 
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analysis (p<0.0001) (Table 3-5). This is our best estimate of an independent effect. 
There were no statistically significant associations between eGFR and RBC GPx, SOD 
and catalase enzyme activities in patients and controls (Figure 3-2 B, C and D). In 
controls, eGFR was lower in subjects taking anti-inflammatory and/or statin 
medications (p=0.05 and p=0.02, respectively, Table 3-5) and significantly higher in 
males (p=0.001). However, given that the MDRD formula is less accurate when eGFR 
is greater than 60m1/min/1.73m 2, 11 the latter observation should be viewed with some 
caution. 
0 	25 	50 	75 	100 
	
125 	 25 	50 	75 	100 	125 
eGFR (mVmin/1.73m 2) eG FR (mUmin/1.73m 2) 
22. 15000 - x 
o) 
x 	m 
10000- 
0 	*.i' 	 co To °00 0 * 0 0  co x o 00 	 0 wo- 
o xx x 	x 	0 
X X XX x m 
o 0 	 p=0.505 	Cr 
100 	125 	
0 
5 	5 	5 20 7' 
I 
eGFR (mlimin/1.73m 2) 
Figure 3-2: Relationships between eGFR and antioxidant enzyme activities in CKD patients and 
controls. 
(A) plasma GPx, (B) RBC GPx, (C) RBC SOD and (D) RBC catalase. Lines represent linear regression 
and adjusted for age Dashed line = patients, solid line = controls.. 
I 
• 
1500- 
C) 
o 1000- 
m 
• 
500- 
re 
2000— o 0 
p=0.111 	o 0 
01 	<1 ; ›,(c) 
p=0.3240 
GO 8 o 
o 00. 
134 ox x 
8 •: .:- o_. 
t, ::, 0 
0 0 
o 	,x xxx  
x xxx 
X x
x 1 X 6, ..41.;. 
6.. - 	x x 	p=0.88.5 
0 2 	x 
25 	s
.
o 	A 	itio 	125 
1 
eGFR (ml/min/1.73m 2 ) 
74 
Table 3-5: Multivariate analysis derived statistically significant associations 
with eGFR in CKD patients and controls with variables selected for 
inclusion determined through stepwise regression. 
Controls CICD patients 
GPx1 Pro197Leu 
Pro/Pro 
Pro/Leu 1.08 (0.65-1.78) 
Leu/Leu 0.65 (0.33-1.26) 
Antioxidant Activities 
Plasma GPx Activity 1.33 (1.01 - 1.74)* 2.63 (1.80 - 3.84)** 
RBC SOD Activity 0.74 (0.52 - 1.05) 
Co-variates 
Age 0.36 (0.27-0.50)** 1.23 (0.96-1.58) 
Gender (male) 1.53 (91.19-1.96)* 0.93 (0.72-1.20) 
Still smoking 3.67 (1.43-9.37)* 
Causes of CKD 
T1DM 1.14 (0.38-3.38) 
Medications 
Erythropoietin 0.29 (0.17-0.49)** 
Statin 0.44 (0.22-0.90) $ 
Anti-inflammatory 0.11 (0.01-1.02)* 
Constant 70.24 (67.86-72.62) 39.43 (36.26-42.61) 
These associations were estimated using ordinal logistic regression due to 
skewness and heteroskedasticity. Blanks were data excluded from logistic 
regression analysis. Other exclusions: RBC GPx and catalase activities; SOD and 
catalase genotypes; co-variants: given up smoking; causes of CKD: 
glomerulonephritis, 12DM, vascular, polycystic kidney disease, uncertain, other 
and analgesic nephropathy; co-morbidities: T2DM medications: angiotensin II and 
ace inhibitors. The odds ratio (OR) and 95% confidence intervals (CI) co-variates 
shown in the model were selected by stepwise regression. Constant, is mean eGFR 
when all other confounders was minimum or zero. 5p=0.05; *p<0.05; **p<0.0001 
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When data from patients and controls was combined, plasma GPx activity was 
significantly reduced in stages 3, 4 and 5 CKD compared with stage 1 (OR 0.14, 95% 
CI 0.07 to 0.29; OR 0.03, 95% CI 0.02 to 0.07; OR 0.01, 95% CI 0.04 to 0.02, 
respectively, Figure 3-3 A). RBC GPx activity was significantly higher in stages 3, 4 
and 5 CKD compared with stage 1 (OR 2.55, 95% CI 1.37 to 4.73; OR 2.30, 95% CI 
1.13 to 4.67; OR 3.05, 95% CI 1.14 to 8.13, respectively, Figure 3-3 B). Participants 
with stages 3 and 4 CKD had significantly higher SOD activity compared with stage 1 
(OR 4.01,95% CI 1.91 to 8.42; OR 2.69, 95% CI 1.21 to 6.00, respectively, Figure 3-3 
C). SOD activity for stage 5 CKD was also higher but this was not statistically 
significant (OR 1.86, 95% CI 0.73 to 4.67). Catalase activity was similar at all stages of 
CKD (Figure 3-3 D). 
Plasma GPx was significantly reduced in the total participant population that carried the 
GPx1 Leu/Leu genotype, compared with participants with the Pro/Pro and Pro/Leu 
genotypes (OR 0.23, 95% CI 0.10 to 0.51, p<0.001; OR 0.21, 95% CI 0.09 to 0.47, 
p<0.001, respectively). However, when patient and control plasma GPx data were 
examined separately, there were no significant differences in GPx activities between 
GPx1 genotypes. Table 3-6 shows that when confounding variables were taken into 
account, plasma GPx activity was only significantly reduced in patients with the 
catalase C/T genotype (p=0.042). 
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Table 3-6: Multivariate analysis derived statistically significant associations between antioxidant enzyme activities in CKD patients and controls with variables selected for 
inclusion determined through stepwise regression. 
Plasma GPx 
Control 	 CKD 
RBC GPx 
Control 	 CKD 
RBC SOD 
Control 	 CKD 
RBC Catalase 
Control 	 CKD 
GPx1 Pro197Leu 
Pro/Pro 
0.53 0.55 2.07 1.42 
Pro/Leu (0.32-0.85)* (0.33-0.92)* (1.27-3.36)* (0.87-2.32) 
11.52 
Leu/Leu (2.73-48.59)* 
SOD2 Alal6Val 
Ala/Ala 
1.13 
AlaNal (0.43-2.97) 
2.88 
Val/Val (1.06-7.82)* 
Catalase C-262T 
C/C 
0.44 2.25 0.20 0.40 
C/T (0.20-0.97)* (0.98-5.14) (0.11-0.36)** (0.23-0.68)* 
0.30 2.76 0.13 0.29 
T/T (0.02-3.09) (1.07-7.11)* (0.06 - 0.27)** (0.13-0.66)* 
Co-variants 
0.74 0.93 1.25 0.82 0.93 1.26 0.87 
Age (0.53-1.02) (0.69-1.25) 1.01 (0.77-1.32) (0.85-1.84) (0.60-1.10) (0.74-1.16) (0.96-1.66) (0.70-1.08) 
0.81 1.22 0.79 1.04 0.95 0.89 0.98 
Gender (male) (0.50-1.30) (0.88-1.71) 1.02 (0.80-1.30) (0.57-1.09) (0.82-1.31) (0.74- 1.21) (0.69-1.14) (0.76-1.26) 
0.44 
Given up smoking (0.23-0.85)* 
0.16 
Still smoking (0.02-1.17) 
Co-morbidities 
0.63 1.65 
High blood pressure (0.36-1.12) (1.01-2.69)* 
Angina/Cardiac 
conditions 
Medication 
Erythopoietin 
Ace inhibitors 
Anti inflammatory 
2.16 
(1.11-4.19)* 
0.34 
(0.18-0.63)* 
1.47 
(0.73-2.96) 
1.84 
(0.91-3.75) 
0.25 
(0.09-0.65)* 
0.74 
(0.45-1.20) 
1.87 
(1.00-1.00)* 
6.50 
(2.42-17.41)** 
Constant 911 
(886-937) 
708 
(658-758) 
59.74 
(56.44-63.04) 
63.68 
(54.00-73.37) 
1037 
(986-1089) 
1133 
(1061-1204) 
10506 
(9965-11047) 
9012 
(8420-9604) 
The associations were estimated using ordinal logistic regression due to skewness and heteroskedasticity. Blanks were excluded from stepwise regression analysis other 
exclusions: causes of CKD: glomerulonephritis, T1DM, T2DM vascular, uncertain, other and analgesic nephropathy; co-morbidities: 12DM medications: angiotensin II 
and statins. The odds ratio (OR) and 95% confident intervals (CI) co-variates shown in the model were selected by stepwise regression. Constant, is mean of the 
antioxidant activity when all other confounders was minimum or zero.*p<0.05; **p<0.0001 
Figure 3-4 A shows that RBC GPx activity was significantly reduced in controls with 
the Pro/Leu GNI genotype compared with Pro/Pro (OR 0.58, 95% Cl 0.37 to 0.92, 
p=0.02). This effect persisted in control participants with the Pro/Leu genotype when 
adjusted for all confounding variables (p=0.009) (Table 3-6). Furthermore, multivariate 
analysis showed that RBC GPx activities in patients with the SOD2 Val/Val and 
catalase T/T genotypes were significantly higher when compared with their respective 
other heterozygote and homozygote genotypes (p=0.037 and p=0.035, respectively). 
RBC SOD activity in patients with the GPx1 Pro/Leu genotype had significantly higher 
SOD activity compared with patients with the GPx1 Pro/Pro genotype (OR 2.18, 95% 
CI 1.36 to 3.50, p=0.001) (Figure 3-4 B). Patients with the GPx1 Leu/Leu genotype also 
had significantly higher SOD activity compared to those with either the Pro/Pro or 
Pro/Leu genotypes (OR 10.24, 95% CI 3.13 to 33.51, p<0.001 and OR 4.69, 95% CI 
1.47 to 14.94, p=0.009, respectively). The opposite was found in controls with the GPx1 
Pro/Leu genotype, who had significantly reduced SOD activity compared with the 
Pro/Pro genotype (OR 0.57, 95% CI 0.36 to 0.91, p=0.019). Table 3-6 shows that after 
multivariate analysis, the effects persisted in both patients and controls, with this being 
our best estimates of independent effects. 
Applying univariate analysis, catalase activity was significantly reduced in all participants 
with both the catalase C/T and T/T genotypes, compared with catalase C/C genotype (OR 
0.35, 95% CI 0.25 to 0.49, p<0.001; OR 0.32, 95% CI 0.21 to 0.49, p<0.001, respectively). 
Catalase activity was also significantly reduced in both patients and controls separately, 
with both catalase C/T and T/T genotypes compared with C/C genotype (patients: OR 0.45, 
95% CI 0.28 to 0.72, p=0.001; OR 0.48, 95% CI 0.24 to 0.99, p-A:1.049, respectively; 
controls: OR 0.22, 95% CI 0.13 to 0.38, p<0.001; OR 0.15, 95% CI 0.08 to 0.029, p<0.001, 
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respectively) (Figure 3-4 C). Table 3-6 shows that this effect persisted after multivariate 
analysis, with both patients and controls with the catalase C/T and T/T genotypes having 
significantly reduced catalase activity compared with C/C genotype (patients: p=0.001; 
p41003; controls both: p<0.0001, respectively). 
3.5 Discussion 
This is the first study to examine and compare relationships between antioxidant enzyme 
genotypes and activities in CKD patients and a control population. The major findings 
were; 1) patients with CKD were more likely to have the GPx Leu/Leu genotype, 2) CKD 
patients with the GPx1 Leu/Leu genotype had reduced kidney function compared to those 
with Pro/Leu genotype, 3) kidney function was better in CKD patients with the SOD2 
Val/Val genotype compared to those with the Ala/Ala genotype, and 4) there were 
significant differences between the antioxidant enzyme profiles of CKD patients compared 
with controls. These were independently related to kidney function and genotype. 
The small number of individuals with the GPx1 Leu/Leu genotype limits the significance 
of the greater prevalence of this genotype in CKD and poorer kidney function in these 
patients. Previous studies also reported a low prevalence of this genotype. Studies 
investigating T2DM37 and bladder cancer137 reported no individuals (total of 606 Japanese 
patients and controls) with the Leu/Leu genotype. In contrast, the frequency of the GPx1 
Leu/Leu genotype in Caucasians is higher, approximately 10% of control or disease 
groups. 183 ' I "' 189 In the present study, the frequency of the Leu/Leu genotype in both 
patients and controls was lower than predicted by Hardy-Weinberg analysis which may 
have been due to consanguinity, assortative mating and small sample size with the latter 
being the most likely cause of this genetic drift. 
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Figure 3-4: Comparison of antioxidant activities in different genotypes. 
(means with standard deviation bars). (A) RBC GPx in GPx1 genotype, (B) 
RBC SOD in GNI genotype and (C) RBC catalase in catalase genotype. 
Error bars show standard deviation. 
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The Leu/Leu GPx1 genotype was found to be associated, non-significantly, with 
reduced eGFR compared to Pro/Leu genotype in CKD patients. Although no studies 
have investigated the relationship between GPx1 Pro197Leu genotype and CICD, five 
studies have investigated the relationship between the GPx1 Pro197Leu genotype and 
diabetes. Two of these have reported associations between the GPx1 Pro/Leu genotype 
and cardiovascular disease in diabetes. 37. 154 In the current study, the five patients with 
the Leu/Leu genotype had diabetes as their cause of CICD and four patients were in 
stage 4 of CICD. 
Kidney function in CKD patients with the SOD2 Val/Val genotype was increased 
(p=0.074) compared to those with the Ala/Ala genotype. Although no previous studies 
have investigated the relationship between the SOD2 Alal6Val genotype and CKD, two 
studies found that the ValNal genotype or Val allele were associated with a 
significantly increased risk of developing diabetic nephropathy. 121, 123 sixty cK,D 
patients from the present study were carrying the ValNal genotype, with only nine 
having diabetes as their primary cause, suggesting the current finding may not be linked 
to diabetes. 
There were no differences in kidney function between the different catalase genotypes 
in CICD patients. Perianayagam and co-workers77 reported similar lack of association 
between the catalase C-262T genotype and acute renal failure. 
Plasma GPx activity was approximately 16% lower in CICD patients compared to 
controls and there was a strong positive association between plasma GPx activity and 
eGFR in CKD patients (but not in controls). The findings that plasma GPx activity was 
significantly reduced in the total participant population in stages 3, 4 and 5 CICD when 
compared with stage 1, is supported by previous studies reporting a parallel decline in 
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plasma GPx activity and kidney function in CICD patients. 35, 53, 62, 64-66, 204, 205 The 
majority of these case-control studies examined small CKD populations (around 50 or 
less).35 ' M, 204 Only two studies consisted of 150 or more CICD patients, 53 ' 62 and only 
30 healthy participants as controls, compared with the present study where 224 controls 
were studied. The most likely explanation for the decline in plasma GPx activity is that 
the kidney is the main source of production of plasma GPx, and when kidney function 
decreases, there is a corresponding decline in plasma GPx activity. 39 
RBC GPx activity was significantly higher in CICD patients than controls. Previous 
studies examining RBC GPx activity in CKD have produced equivocal results with two 
studies reporting similar relationships 53 ' 63 but another study finding that RBC GPx 
activities were significantly reduced in CKD patients. 65 However, the present study 
involved both a much larger CICD patient population and a CICD control group. In 
addition, when the total study population (patients and controls) was stratified into 
stages of CKD, RBC GPx activity was significantly higher in stages 3-5 compared with 
stage 1. A possible explanation for the higher RBC GPx associated with lower kidney 
function could be the reduced life expectancy and more regular replacement of the RBC 
(hence RBC GPx) in subjects with declining kidney fitnction. 15 ' 16 
RBC SOD activity was significantly increased in CICD patients compared to controls, 
and when examined in the total participant population was significantly higher in stages 
3 and 4 CICD than stage 1. In contrast, Ceballos-Picot et al.53 reported that RBC SOD 
activity was not significantly different in CICD patients and controls, although the study 
was limited by a small number of controls (30). 
RBC catalase activity, in this study was found, to be significantly lower in CKD 
patients compared with the control group. In a previous study, catalase activity in 
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children with CKD (aged 5-18 years) also reported significantly reduced RBC catalase 
activity compared to age matched controls. 85 One potential explanation for the decrease 
in RBC catalase activity in CKD, compared to the increase in both RBC GPx and SOD 
activities, is that catalase may degrade in very high hydrogen peroxide environments. 206 
In addition, catalase is preferentially exploited in a high hydrogen peroxide environment 
as it requires two hydrogen peroxide molecules when converting same to water and 
oxygen. Therefore, catalase becomes saturated more quickly compared with GPx and 
SOD antioxidants in the shortened RBC life span in CICD.15' 16,47 
The presence of SNPs in antioxidant enzymes had a significant effect on specific 
enzyme activities (genotype-phenotype association) in CKD patients and controls. 
There were no significant relationships between GPx1 genotypes and both plasma and 
RBC GPx activities in patients. In contrast, control participants' RBC GPx activity was 
reduced in GPx1 Pro/Leu genotype compared with Pro/Pro genotype. A similar finding 
was reported in breast cancer patients with RBC GPx activity reduced with the Leu 
allele compared with Pro allele.74 Furthermore, the GPx1 genotype in both patients and 
controls was significantly associated with RBC SOD activity. However, in patients with 
the GPx1 Pro/Leu genotype, SOD activity increased compared with Pro/Pro genotype 
and SOD activity was reduced in control subjects with Pro/Leu genotype compared with 
Pro/Pro genotype. To our knowledge, this significant relationship has not been reported 
previously, but the reason for this association is unclear and requires further 
investigation. 
Finally, we observed reduced catalase activity in CKD patients and controls with C/T 
and T/T genotypes compared with C/C. Perianayagam et al. 77 reported similar findings 
in acute kidney injury patients, with the T allele having decreased catalase enzyme 
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activity compared with C/C genotype. On the other hand, Forsberg and co-workers I91 
reported catalase activity was significantly higher in Swedish men with the T allele 
compared with C allele. This variation in genotype-phenotype association may be due to 
the measurement of protein levels of catalase in whole blood by Forsberg and co-
workers, whereas enzyme activity in RBC was measured in the current study. 
In conclusion, antioxidant genotype frequencies were similar in CKD patients and 
controls, and a non-statistically significant trend towards lower eGFR was found in 
patients with the GPx1 Leu/Leu genotype and higher eGFR in patients with the SOD2 
Val/Val genotype. In addition, CKD was associated with impaired plasma GPx and 
RBC catalase activities and enhanced RBC GPx and SOD activities compared with 
general population controls. The marked differences in antioxidant enzyme activities of 
CKD patients compared with controls suggests impaired kidney function has a 
significant effect on antioxidant status. Further studies of antioxidant genotypes and 
activities in a larger CKD population are warranted. 
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CHAPTER 4: GLUTATHIONE PEROXIDASE, 
SUPEROXIDE DISMUTASE AND CATALASE 
GENOTYPES AND ACTIVITIES ON THE 
PROGRESSION OF CKD 
4.1 Abstract 
Background and Objectives: Chronic kidney disease (CI(D) is a significant public 
health issue that affects an estimated 11 percent of adults over the age of 25 years in 
Australia. Oxidative stress has been linked to the progression of a number of diseases, 
including CKD. The antioxidant enzymes, superoxide dismutase (SOD), glutathione 
peroxidase (GPx) and catalase, together form the primary defence system against 
reactive species and oxidative stress. Methods: We examined the relationship between 
antioxidant enzyme single nucleotide polymorphisms (GPx1 Pro197Leu, SOD2 
Ala! 6Val and catalase C-262T), changes in antioxidant activities and the progression of 
CKD (decline in estimated glomerular filtration rate (eGFR)) in 185 patients over 12 
months. Results: CKD patients with the SOD2 Ala/Val and VaVVal genotypes had a 
significantly greater decline in kidney function compared to those with the Ala/Ala 
genotype (Ala/Val compared with Ala/Ala OR 0.35, 95% Cl 0.19 to 0.64, p=0.001; 
Val/Val compared with Ala/Ala OR 0.25, 95% Cl 0.10 to 0.65, p=0.005). The 
progression of CKD was not influenced by SNPs of the GPx1 or catalase genes studied. 
There was a direct relationship (multivariate analysis), between the rate of change of 
plasma GPx activity and the rate of change of eGFR over the 12 month period 
(p=0.025). Conclusion: CKD patients with the SOD2 Ala/Val and Val/Val genotypes 
have a greater decline in kidney function than those with the Ala/Ala genotype. 
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4.2 Introduction 
The antioxidant enzyme SNPs, SOD2 Alal 6Val, GPx1 Pro197Leu and catalase C-
2621, and changes in the activities of SOD, GPx and catalase, have been associated 
with altered progression and/or risk of several diseases, including breast cancer, 74 lung 
cancer,75 diabetic neuropathy76 and acute kidney injury!' Moreover, the potential links 
between the activities of antioxidant enzymes and CKD have been the subject of several 
case-control studies. 35 ' 53 ' 64-66' 207 However, to date, there have been no studies 
addressing the role of antioxidant enzyme SNPs and activities in the progression of 
CI(D. Thus, the aims of the present study were to determine whether the progression of 
kidney disease, defined for this study as decline in eGFR over one year, was (a) linked 
to specific genotypes resulting from the aforementioned GPx 1, SOD2 and/or catalase 
SNPs, and (b) associated with altered GPx, SOD and/or catalase activities. 
4.3 Methods 
The protocols used for obtaining blood samples and methods for measuring antioxidant 
activities, genotyping and statistical analysis are detailed in Chapter 3 (section 3.2.2— 
3.2.3). 
4.3.1 Study Subjects 
All CKD patients recruited (261) were asked to provide four blood samples over 
approximately 12 months. Hence, there was bias towards patients at later stages of 
CKD. The inclusion criterion was that they provided a minimum of three samples, more 
than 1 month apart over this period, in order to determine the rate of change of eGFR 
and antioxidant activities. (Of the 261 patients recruited, eight died, three commenced 
dialysis, two received transplants and 32 provided insufficient samples. Hence, the 
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study population consisted of 185 CKD patients. The demographics of this population 
are detailed in Table 4-1. 
Table 4-1: Demographics and clinical characteristics of CKD 
patients. Smoking status was only available on 104 CKD 
patients (% expressed accordingly). 
(n=185) 
Gender (Male) 
Age (years) 
Primary causes of CICD 
Vascular 
Glomerulonephritis 
T2DM 
95 (52%) 
69.5±12.0 
(range 30-80) 
69 (37%) 
33 (18%) 
32 (18%) 
T1DM 8(4%) 
Reflux nephropathy 9 (5%) 
Polycystic kidney disease 4 (2%) 
Analgesic nephropathy 2 (1%) 
Uncertain 4(2%) 
Other 24 (13%) 
Medications 
Erythropoietin 80 
ACE inhibitors 74 
Statins 61 
Angiotensin receptor blockers 52 
Anti-inflammatory steroids 14 
Smoking Status 
Never Smoked 57 (55%) 
Given up 39 (37%) 
Current Smoker 8 (8%) 
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4.3.2 Statistical Analysis 
Hardy-Weinberg analysis was carried out on all genotype population groups. SOD2 and 
catalase genotypes for both controls and patients were within the Hardy-Weinberg 
equilibrium. Sample size calculation predicted that in order to detect a 2.4-fold increase 
in eGFR decline, 19 homozygous mutations and 231 patients of other genotypes were 
required. Whilst we aimed to recruit an even larger number of patients, 261 patients 
from North, North West and North East of Tasmania were recruited (see Appendix 2). 
The majority of the statistical analysis has been described in section 3.3.4. When 
determining associations with rate of change of either eGFR or antioxidant enzyme 
activities, age, gender, smoking status, change over time of all antioxidant activities, 
initial eGFR, initial antioxidant activities, antioxidant genotypes, primary cause of CKD 
and medications were presented for selection by stepwise regression for inclusion in the 
multivariate model. P-values were corrected for multiple comparisons using the Holm 
method. All statistical analyses were performed using Stata 10.1/IC (StataCorp LP, 
College Station, TX, USA). 
4.4 Results 
Over the 12 month study period, eGFR declined in 61% of the patients, increased in 
24% and was stable in 15%. Patients with the Ala/Val and ValNal SOD2 genotypes 
had a more rapid decline in kidney function compared to those with the Ala/Ala 
genotype (Ala/Val compared with Ala/Ala OR 0.35, 95% CI 0.19 to 0.64; Val/Val 
compared with Ala/Ala OR 0.25, 95% CI 0.10 to 0.65) (Table 4-2, Figure 4-1 A). 
Furthermore, this effect persisted when adjusted for all confounding variables with 
Ala/Val and Val/Val genotypes linked to a faster rate of decline in kidney function 
(p=0.002; p=0.006, respectively) (Table 4-3). Furthermore, this effect persisted when 
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adjusted for all confounding variables with Ala/Val and Val/Val genotypes linked to a 
faster rate of decline in kidney function (p3.002; p1).006, respectively) Thirty seven 
percent of the study population had vascular disease as their primary cause of CKD, 
with 48% and 30% having the Ala/Val and ValNal genotypes, respectively. However, 
the prevalence of these genotypes was similar for both CKD of vascular origin and the 
total study population (Ala/Val, 50% and Val/Val, 26%) (Table 4-2). Progression of 
CKD was not influenced by GPx1 or catalase SNPs (Figure 4-1 B and C, respectively). 
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Table 4-2: Antioxidant enzyme genotypes and changes in kidney function and antioxidant enzymes (mean±SD) 
GPx1 Pro197Leu Genotypes 
Pro/Pro 	Pro/Leu 	Leu/Leu 
SOD2 Alal6ValGenotypes 
Ala/Ala 	Ala/Vat 	Val/Val 
Catalase C-262TGenotypes 
C/C 	C/T 	TIE 
(n=82) (n=83) (n=4) (n=40) (n=85) (n=44) (n=109) (n=53) (n=7) 
Age 69.6 70.0 55.7 70.8 68.1 70.8 71.5 66.5 60.7 
(±11.8) (+11.6) (±15.8)* (±12.1) (+12.2) (±11.1) (+10.0) (+14.0) (+15.0) 
Gender - male (%) 40 47 1 20 46 22 57 26 5 
Baseline 
eGFR (ml/min/1.73m 2) 30.16 31.54 24.50 28.29 31.43 31.40 31.80 27.69 38.20 
(+13.63) (+13.94) (±6.14) (+11.85) (+13.93) (+14.62) (+14.32) (+11.21) (+18.43) 
Plasma GPx (U/L) 619.06 600.79 544.70 580.31 622.28 609.67 620.07 587.75 588.71 
(+179.86) (+175.03) (+94.66) (+165.92) (+186.97) (+164.14) (+178.09) (+170.22) (+190.30) 
RBC GPx (U/g Hb) 72.78 73.67 64.91 73.58 72.47 73.63 74.01 69.46 84.39 
(+19.96) (+25.34) (+34.88) (+26028) (+24.51) (+16.53) (+23.31) (+22.34) (+20.74) 
SOD (U/g Hb) 1153 1266 1408 1299 1200 1165 1232 1173 1256 
(+262.89) (+331.06) (+223.27) (+332.19) (+312.31) (+241.03) (+319.30) (+281.61) (+152.02) 
Catalase (U/g Hb) 9200 9444 9327 9267 9285 9448 9437 8956 10335 
(+3650) (+3273) (+3861) (+2758) (+3835) (+3310) (+3536) (+3149) (+4525) 
Change over year 
eGFR -3.41 -2.90 1.99 1.68 -3.61 -6.21 -2.94 -3.26 -2.77 
(ml/min/1.73m 2/year) (+10.86) (±9.43) (+12.87) (±6.06) (±7.91)** (+14.79)* (+10.49) (+10.17) (+5.41) 
Plasma GPx -16.84 -38.04 -111.63 -17.21 -33.33 -33.26 -25.20 -51.74 72.08 
(U/L/year) (+259.96) (+301.61) (+79.14) (+354.60) (+242.88) (+269.85) (+278.00) (+291.73) (+144.73) 
RBC GPx -2.21 -8.94 -0.77 -7.67 0.61 -15.25 -8.35 1.60 -15.95 
(U/g Hb/year) (+40.93) (+41.53) (+55.07) (+38.56) (+42.80) (+40.09) (+39.79) (+44.75) (+37.95) 
RBC SOD 25.07 15.77 -283.78 85.21 27.88 74.27 -42.88 163.36 -250.74 
(U/g Hb/year) (+535.74) (+612.66) (+546.56) (+406.55) (+640.44) (+566.90) (+513.79) (+669.50) (+490.83) 
RBC Catalase -2877 -3031 -2988 -3035 -3031 -3265 -3565 -2168 -2751 
(U/g Hb/year) (+5138) (+5783) (±5287) (±5553) (+5783) (+3554) (+5597) (+4445) (+3569) 
*** (p<0.01) compared with Pro/Pro; ** Significantly different (p<0.001) to Ala/Ala; * Significantly different (p<0.01) to Ala/Ala. 
* 
Ala/Ala 	AlaNal 	VaVVal 
SOD2 Genotype 
Pro/Pro 	Pro/Leu 	Leu/Leu 
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Figure 4-1: Rate of change (A) in eGFR in C1CD patients (n=185) over 12 months for different 
genotypes. 
A) SOD2 Alal6Val genotypes. B) GPx1 Pro197Leu genotypes and C) catalase C-262T genotypes. Data 
adjusted for age. Error bars show standard deviation. **p<0.001, *13=0.009 
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In patients with the GPx1 Leu/Leu genotype (n=5), the rate of change in plasma GPx 
activity was significantly reduced compared with GPx Pro/Pro genotype (OR 0.42, 95% 
CI 0.20 to 0.87, p=0.02). When adjusted for all confounding variables, the change in 
plasma GPx activity over the 12 month study period was significantly reduced in 
patients with the GPx1 Leu/Leu genotype (p.026) (Table 4-3). However, changes in 
RBC GPx, RBC SOD and RBC catalase activities over time were not influenced by any 
of the SNPs when either univariate or multivariate analysis was performed. 
When simple univariate analysis was performed, a trend towards a relationship between 
change in plasma GPx activity and change in eGFR over the 12 month study period was 
apparent (p=0.069) (Figure 4-2 A). However, when all confounding variables were 
taken into account, there was a significant association between the decline in eGFR over 
time and the decline in plasma GPx activity (p=0.025) (Table 4-3), this being our best 
estimate of an independent effect. Conversely, the changes in RBC GPx, RBC SOD and 
RBC catalase activities were not associated with the change in eGFR over 12 months 
(Table 4-3). (Figure 4-2 B, C and D, respectively). 
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Figure 4-2: Relationship between rate of changes (A) of antioxidants and eGFR 
A) plasma GPx, B) RBC GPx, C) RBC SOD and D) RBC catalase activities over 12 months and A in 
eGFR over the same period in CKD patients. Odds ratio (OR, with 95% confidence) and p values indicate 
significance of relationships. 
Patients with higher eGFR on entry into study (baseline) had a faster decline in kidney 
function over 12 months (p=0.046) (Figure 4-3). However, baseline antioxidant activity 
did not appear to influence the rate of decline of eGFR over the 12 month study period. 
On the other hand, the rate of change of all four enzymes activities was inversely related 
to the activity of the individual enzyme at baseline (plasma GPx: p<0.0001; RBC GPx: 
p<0.0001; RBC SOD: p=0.004 and RBC catalase: p<0.0001) (Figure 4-4 A, B, C and 
D, respectively). This remained significant (p, all<0.0005) when adjusted for all 
confounding variables (Table 4-3). 
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Figure 4-3: Relationship between rate of change (A) in eGFR over 12 months and eGFR on entry 
into the study (baseline measurement) for C1CD patients (n=185). 
Odds ratio (OR, with 95% confidence intervals brackets) and p values indicate significance of 
relationships. 
Changes in individual antioxidant activities were influenced by the baseline activity of 
other antioxidant enzymes. Higher baseline catalase activity was associated with 
increasing plasma GPx (p=0.017) over 12 months (Figure 4-4 E). When multivariate 
analysis was performed, this association persisted (p=0.003) (Table 4-3). In addition, 
higher baseline RBC GPx activity was associated with declining RBC catalase activity 
over 12 months (p<0.0001) (Figure 4-4 F). Finally, when adjusted for all confounding 
variables, there was a positive association between baseline SOD activity and catalase 
activity over the 12 month study period (p=0.017) (Table 4-3). 
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Table 4-3: Multivariate analysis derived associations between rate of change (A) of eGFR and A of antioxidants activities compared 
with baseline measurements and A of antioxidant. 
A eGFR 
(ml/min/1.73m 24'ear) 
OR (95% CI) 
A Plasma GPx 
(U/L/year) 
OR (95% CI) 
A RBC GPx 
(U/g Hb/year) 
OR (95% Cl) 
A RBC SOD 
(U/g Hb/year) 
OR (95% CI) 
A RBC Catalase 
(U/g Hb/year) 
OR (95% CI) 
GPx1 Pro197Leu 
Pro/Pro 
Pro/Leu 0.66 (0.37-1.19) 0.73 (0.41-1.29) 
Leu/Leu 0.15 (0.03-0.80)* 0.61 (0.22-1.67) 
SOD2 Alal6Val 
Ala/Ala 
Ala/Val 0.37 (0.20-0.70)** 
ValNal 0.26 (0.10-0.67)** 
Catalase C-262T 
C/C — 
C/T 0.66 (0.35-1.25) 1.14 (0.63-2.06) 1.53 (0.87-2.70) 
TI' 1.09 (0.36-10.04) 0.62 (0.12-3.22) 1.77 (0.60-5.25) 
A eGFR 
(ml/min/1.73m 2/year) 1.49(1.05-2.11)* 1.39 (0.84-2.31) 0.66 (0.43-1.02) 
A Antioxidants 
Plasma GPx (U/L/year) 0.77 (0.51-1.15) 
RBC GPx (U/g Hb/year) 1.53 (1.13-2.06) 1.49 (1.09-2.03)* 
RBC SOD (U/g Hb/year) 0.68 (0.48-0.97)* 1.55 (1.05-2.29)* 
RBC Catalase (U/g Hb/year) 1.60 (1.13-2.25)** 
Baseline Measurements 
eGFR (ml/min/1.73m 2) 0.75 (0.53-1.04) 
Plasma GPx (U/L) 0.45 (0.30-0.68)*** 
RBC GPx (U/g Hb) 0.20 (0.12-0.32)*** 0.75 (0.52-1.09) 
RBC SOD (U/g Hb) 0.63(1.14-2.06) 1.44(1.07_1.94)* 
RBC Catalase (U/g Hb) 1.49(1.12-1.74)** 0.34 (0.24-0.59)*** 
Causes of CKD 
Vascular 	 0.83 (0.46-1.52) 	 0.99 (0.54-1.85) 
T1DM 0.46(0.16-1.29) 	 7.80 (1.97-30.90)** 0.87 (0.10-7.90) 
T2DM 	 0.62(0.26-1.50) 0.90 (0.45-1.79) 0.46 (0.25-0.81)** 	— 
Medications 
Statins 	 1.35 (0.68-2.70) 	 — 
Angiotensin II 	 — 
Ace Inhibiter 1.27 (0.68-2.47) 	 0.97 (0.55-1.70) 	1.17 (0.66-2.10) 
0.49 	 -18.60 	 3.41 	 -51.35 	 -3253 
Constant 	 (-1.85-2.83) 	(-41.84- 79.04) 	(-5.81-12.62) 	(-91.88-194.59) 	(-4184-2321)  
These associations were estimated using ordinal logistic regression due to skewness and heteroskedasticity, with variables selected for 
inclusion by stepwise regression. Blanks and other variables that were not statistically significant in stepwise regression analysis: co-variants: 
age, gender, never smoked, given up smoking, still smoking; causes of CKD: uncertain, other, reflux nephropathy and analgesic 
nephropathy; medications: erythropoietin, anti-inflammatory and ace inhibitors. Constant, is mean change of eGFR and the antioxidant 
activities when all other confounders was minimum or zero 
The odds ratio (OR) and 95% confident intervals (CI) for the associations with eGFR and antioxidants activities in each by separate mode are 
those that were selected by stepwise regression. *p<0.05, **p<0.01 and ***p<0.001. 
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Figure 4-4: Relationships between rate of change (A) in antioxidant activities over 12 months and 
antioxidant activity measurements on entry into study (baseline) in CKD patients. 
A) A and baseline plasma GPx activity; B) A and baseline RBC GPx activity; C) A and baseline SOD 
activity; D) A and baseline catalase activity; E) A plasma GPx activity and baseline catalase activity; F) A 
catalase activity and baseline RBC GPx activity. Odds ratio (OR) and 95% confidence intervals and p values 
indicate significance of relationships. 
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The rate of change in plasma GPx activity was inversely linked to the change in both 
RBC SOD and catalase activities over 12 months (p=0.025 and p=0.041, respectively) 
(Figure 4-5 A and B, respectively). However, when all confounding variables were 
taken into account, this relationship did not persist (Table 4-3). In addition, the change 
of RBC GPx activity displayed a positive association with change in both RBC SOD 
and RBC catalase activities (p=0.02; p<0.0001, respectively) (Figure 4-5 C and D, 
respectively), which persisted when the data was subjected to multivariate analysis 
(p=0.028; p=0.008, respectively; Table 4-3). 
When diagnosed as the primary cause of CM), 11DM was associated with an increase 
in RBC GPx activity over time (p=0.003, Table 4-3) whereas T2DM was associated 
with a faster decline in SOD activity over time (p=0.008, Table 4-3). 
Figure 4-5: Relationships between rates of change (A) in antioxidant activities over 12 months in 
CKD patients. 
A) Plasma GPx and RBC SOD; B) RBC GPx and RBC SOD; and C) RBC catalase and RBC GPx. Odds 
ratio (OR), and 95% confidence intervals brackets) and p values indicate significance of relationships. 
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4.5 Discussion 
This is the first study to investigate antioxidant enzyme genotypes and activities in 
relation to the progression of kidney disease over an extended period (12 months). The 
major findings were that: 1) CKD patients with the SOD2 Ala/Val and Val/Val 
genotypes had a significantly greater decline in kidney function compared to patients 
with the Ala/Ala genotype, 2) declining plasma GPx activity was associated with a 
decline in kidney function, and 3) declining kidney function over 12 months was 
associated with increasing RBC SOD activity, when multivariate analysis was 
performed. 
The most significant finding was the accelerated decline in kidney function in patients 
with either SOD2 Ala/Val or Val/Val genotypes. Why this polymorphism predisposes 
individuals to CKD (and other diseases) is not clear. It has been suggested that the 
amino acid change from Ala to Val may have an effect on the structure of SOD2, 
changing an alpha helix structure to a beta sheet. 208 Furthermore, the Ala allele has been 
associated with higher MnSOD mitochondrial activity. Therefore the Ala allele may be 
more protective against oxidative stress, 209 and against progression of diseases that 
have been linked to oxidative stress, including CK.D. In addition, the Val allele may 
have a direct effect on the transport of MnSOD into the mitochondria. 208 In rats exposed 
to chronic hypoxia, expression of MnSOD in the kidney is increased which may protect 
the kidney from oxidative damage caused by superoxide. 67 ' 210 Hence, future studies 
should examine whether MnSOD, which is predominantly of mitochondrial origin, is 
up-regulated in the kidney and whether it is affected by the Alal 6Val genotype MnSOD 
(SOD2). Although this study measured RBC SOD activity this does not contain 
MnSOD (SOD2), 
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An alternative explanation for this decline is co-existing vascular disease and diabetes 
(T1DM and T2DM), which were the primary cause of CKD in 22% and 37% of 
patients, respectively. In the present study, the Ala/Val and ValNal SOD2 genotypes 
accounted for 78% of patients with CKD of vascular origin. A large number of studies 
(>70) have investigated the relationship between the SOD2 Alal6Val genotype and 
disease, including three relating to CVD, 71-73 and seven to T1DM and T2DM. 121-126 A 
large case-control study involving 989 participants (504 hypertensive; 485 controls) 
found a significant relationship between carotid artery intima-media thickness (CIMT), 
a measure of atherosclerotic burden, and the Val allele in women that had high levels of 
LDL cholesterol (p=0.03). 72 Whilst another study found that haemochromatosis patients 
(217) with the Val allele had an increased risk of cardiomyopathy compared with those 
with the Ala allele, only 27 patients in total had cardiomyopathy, and eleven (30%) of 
these had the Val/Val genotype. 73 A cohort study involving 252 participants, reported 
that the Ala/Val and Val/Val genotypes were associated with increased levels of 
oxidised LDL compared with Ala/Ala genotype in patients with oxidised LDL 
<0.5nmol/mg.71 Finally, Mollesten and co-workers' 121 case-control study found an 
increased risk of diabetic nephropathy in T1DM patients with the SOD2 ValNal 
genotype. In addition, another study reported the frequency of the Val/Val genotype was 
found to be higher in T2DM patients with diabetic nephropathy. 123 However, the present 
study provides evidence that links the SOD2 Ala/Vat and Val/Val genotypes to both 
CVD and diabetes, in addition to CKD. 
Declining plasma GPx was positively associated with declining eGFR over 12 months. 
Previous case-control studies involving a single measurement in time, found a direct 
relationship between reduced plasma GPx activity and decreased kidney function in 
CKD patients. 35 ' 53 ' 62 64-66' 204 Most of these previous studies involved 50 or less CKD 
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patients,35 . 64-66 ' 204 and in the two studies involving 150 or more CKD patients, the 
control group was small (-30 healthy participants). 53 ' 62 The present study is the first, to 
our knowledge, to show a direct association between faster progression of kidney 
disease and lower plasma GPx over an extended timeframe. A likely explanation for the 
decline in plasma GPx activity is that the kidney is the main source of production of 
plasma GPx, and hence, when kidney function decreases, plasma GPx activity 
decreaseS.39 
Interestingly, declining eGFR over 12 months was shown by the multivariate analysis to 
be associated with increasing RBC SOD activity. A case-control study by Ceballos-
Picot et al.53 previously reported that RBC SOD activity was unchanged in CKD, but 
there have been no previous cohort studies. One possible explanation for the current 
finding could be the reduced life expectancy and reduced deformability of RBCs in 
subjects with declining kidney function. 16, 211 As mature erythrocytes being anucleate, 
protein synthesises is thought to take place during erythropoiesis. 2I2 Consequently, RBC 
SOD is not depleted and therefore, high levels of the antioxidant are still present in 
RBC. 
In univariate analysis, baseline eGFR was shown to be inversely related to change in 
eGFR over 12 months. This association disappeared when all confounding variables were 
taken into account. Our findings suggest that baseline antioxidant enzyme activities are 
associated with declining antioxidant activities over time. Nevertheless, these findings 
may simply be a regression to the mean. Furthermore, the interplay between baseline 
antioxidant activities and changes in other antioxidant activities over time demonstrates 
a strong link between the GPx and catalase activities. This conclusion is supported by 
previous studies that proposed a direct relationship to the oxidant sensitivity of glucose- 
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6-phosphate dehydrogenase (G6PD)-deficiency and impaired catalase activity. G6PD 
maintains levels of glutathione, which is intimately involved in the conversion of H202 
to water and oxygen by GPx.49 
Our overall findings regarding RBC GPx and SOD activities contradict those of 
Karajibani et al.213 who reported that there was no significant correlation between RBC 
SOD and RBC GPx activities in 71 CVD patients and 63 healthy controls. Thus, the 
present study suggests a potential link between RBC antioxidant activities in CKD that 
has not been reported in CVD. However, these findings also suggest that there is a 
direct link between GPx activities and the activities of both SOD and catalase in 
oxidative stress. 
There are a number of factors that may limit the findings of this study. A larger study 
population and an extended study time in subsequent studies are recommended to 
strengthen the antioxidant genotype findings (particularly as the number of GPx1 
Leu/Leu genotypes was so low) and provide a better picture of kidney disease 
progression. In addition, the study population was Caucasian only. Future investigations 
should include other ethnic groups as there is some evidence that the GPx1 Leu/Leu 
genotype may be very limited in Asian populations. Therefore, the associations reported 
here in relation to the GPx1 genotype may not be relevant to Asian or African 
populations. Calculating eGFR using MDRD from serum creatinine also has its 
limitations as a measure of kidney function, compared with radio isotopic methods, 
which are impractical because of cost and logistics. Additionally, the Chronic Kidney 
Disease Epidemiology Collaboration (CKD-EPI) equation is a new and accurate method 
of calculating eGFR and may in the future become the new gold standard. 10' 11 Finally, 
measurement of other enzymes and cofactors involved in the antioxidant enzyme 
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pathways (e.g., G6PD and glutathione) would provide a more complete picture of 
antioxidant status in CKD. 
To conclude, we followed kidney function in 185 CKD patients over 12 months. 
Patients with the SOD2 VaVVal or Ala/Val genotypes had a greater decline in kidney 
function suggesting that SOD2 genotypes may be used to identify CKD patients at risk 
of more rapid disease progression. Being able to tailor a patient's treatment, which 
could include supplementation therapies, might be investigated to determine whether they 
may slow progression of CKD.214 Similarly, a faster decline in kidney function is 
associated with decreasing plasma GPx activity. Hence, enhancing the activity of GPx 
may also slow the progression of kidney disease. 
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CHAPTER 5: THESIS SUMMARY AND CONCLUSION  
5.1 General Discussion 
Kidney disease is potentially fatal and the number of people being diagnosed with CKD 
is increasing every year. The social and personal cost involved varies considerably 
between patients due to their response to treatment and the level of supportive care 
required for everyday activities Furthermore, it costs the Australian government 
upwards of $80,000 per year for every patient that progresses to ESRD, requiring 
replacement therapy by HD, PD or a kidney transplant. 3 Hence, the ability to identify 
patients at risk of rapid disease progression, in addition to identifying people at risk of 
developing CKD, would reduce the strain of community support, enable nephrologists 
to improve treatment and potentially reduce cost to the government. 
In recent years, the role of specific genotypes in the pathogenesis and progression of 
disease has become a major focus for research. This has centred mainly on SNPs, which 
involve a single base substitution, deletion or addition. Therefore, the overall aim of this 
research was to determine whether specific SNPs in antioxidant genes and associated 
changes in antioxidant enzyme activities are implicated in the pathogenesis of CKD and 
/or play a role in the progression of CKD to ESRD. 
5.2 Chapter 3 
The case-control study revealed a significant difference between the GPx1 Leu/Leu 
genotype frequency of CKD patients and controls, with all five subjects possessing the 
Leu/Leu genotype having CKD, and four of these patients in the later stage of CKD 
(eGFR <30mL/min/1.73m2). However, a larger population study is required to reliably 
conclude that the Leu/Leu GPx1 genotype is overrepresented in the CKD population 
and that it may predispose such patients to progress more rapidly to ESRD. In contrast, 
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SOD2 and catalase genotype frequencies in CKD patients were not found to be 
significantly different from controls. However, GPx1 genotype was significantly 
associated with reduced RBC GPx activity in the control population participants with 
the Pro/Leu genotype. This may suggest that the GPx1 Pro/Leu genotype is associated 
with a change in the phenotype of RBC GPx when not in a state of oxidative stress. The 
catalase C-262T SNP was significantly associated with reduced catalase activity 
regardless of whether CKD was present. When a participant possessed either catalase 
C/T or T/T genotypes, they had significantly reduced catalase activity compared to all 
participants with C/C genotype. 
Plasma GPx and RBC catalase activities were significantly lower in CKD patients 
compared with the control population, suggesting an elevated state of oxidative stress in 
the patients. On the other hand, RBC GPx and SOD antioxidant activities were 
increased in CKD patients, which may be due to the reduced viability of RBC observed 
in CKD patients. This seems paradoxical, but, it may be due to the reduced lifespan of 
RBC in CKD patients. The activity of RBC antioxidant enzymes is likely related to the 
lifespan of the RBC (i.e., the younger the RBC, the more activity). Therefore, as CKD 
patients would have overall "younger" RBCs, this may explain the higher antioxidant 
enzyme activity. 
The current study showed that plasma GPx activity was (significantly) linked to the 
decline in kidney function. A possible explanation is that plasma GPx is primarily 
produced in proximal tubules in the kidney. Hence, when kidney function declines, so 
does the production of plasma GPx. 39 This has been reported in a number of previous 
studies, 13, 35, 53, 62, 63, 66 but the present study, to our knowledge, is the first to examine 
such a large CKD population (n=230) and control group (n=224). In contrast, reduced 
kidney function in CKD patients was not associated with changes in activities of the 
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other antioxidant enzymes. Interestingly, RBC SOD antioxidant activity was associated 
with GPx1 genotype in both patients and controls, but the reason for this association is 
unclear and warrants further investigation. Overall, these data suggest that small 
alterations in activity caused by either SNPs or oxidative stress may produce a major 
disturbance in the overall antioxidant status. 
A most surprising finding, unrelated to the primary aim, was that 13% (approximately 
one in seven) of the general (control) population in the North and North West of 
Tasmania had undiagnosed CKD (indeed 30 were in stage 3, based on eGFR 
measurements). This data corroborates the finding of Chadban and co-workers in 2003 1 
that 11% Australians over the age of 25 years are living with CKD stages 3-5 
undiagnosed. 
5.3 Chapter 4 
This cohort study is the first, to our knowledge, to examine kidney function in CKD 
patients over 12 months in relation to antioxidant genotypes and antioxidant enzyme 
activities. 
The major finding of this study was that kidney function was adversely associated with 
the presence of the SOD2 Ala/Val and Val/Val genotypes. However, neither GPx1 or 
catalase genotypes studied had a significant association with the progression of CKD. 
This suggests antioxidant genotype may play a role in the progression of CKD, as 
patients with SOD2 AlaNal or Val/Val genotypes were progressing more rapidly 
towards ESRD. However, with recent large scale studies including HapMap and 1000 
Genomes Project finding evidence that there are numerous Therefore, genotyping might 
help both nephrologists and the patients pursue a more aggressive course in their 
personalised treatment. This study also extends the findings of the case-control study, 
viz, that not only is plasma GPx associated with reduced kidney function, but that a 
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faster decline in plasma GPx activity over time correlates with accelerated progression 
of kidney function. The present study demonstrated significant associations between 
antioxidant genotypes and activities. However, whether altered antioxidant enzyme 
genotypes and/or activities contribute directly to CKD will require further research. 
A dynamic interplay between the three antioxidant enzymes was found, with reduced 
activity of one enzyme (e.g., plasma GPx), leading to an increase in the activity of 
another antioxidant (e.g., RBC SOD or RBC catalase) over time. This may demonstrate 
a direct interaction of the GPx-SOD-catalase antioxidant system during both normal and 
oxidative stress status. 
5.4 Future Research and Limitations 
The present thesis examined a very specific and a limited population in the North and 
North West of Tasmania, Australia. Furthermore, all participants involved in the study 
were Caucasian. Therefore, to strengthen the principal findings of both the case-control 
and cohort studies, it is recommended that further studies should include other ethnic 
groups (e.g., Aboriginal, Torres Straight Island, Asian). Future case-control and cohort 
studies should be larger to strengthen the genetic findings. Although, the current case-
control, investigation had 96% and 94% of the cases and controls, respectively, 
prescribed by the sample size calculation, the cohort study, had less than the required 
sample size. The cohort study population was only 80% (n=185) of the required CKD 
number predicted by the sample size calculation to determine a minimum 2-fold 
increase in the rate of decline of eGFR due to a specific genotype. However, the current 
thesis recruited greater than 90% of the Northern Tasmania's diagnosed CKD 
population (physicians estimate), so further recruitment would have required and 
requiring the involvement of other hospitals and nephrologists which was not accessible 
at the time. In addition, it well is documented and understood that there is a linear 
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decline of kidney function with age. Therefore, in the present study CKD patients were 
age and sex matched with the control population as closely as possible. However, there 
was still a significant age difference between the groups and so all analyses performed 
were adjusted for age. 
With the current trend towards investigating the role of SNPs in disease, a major aim of 
this study was to determine whether knowledge of a patient's antioxidant enzyme 
genotype would assist in the treatment of CI(D. This has been achieved, albeit with 
some limitations. Nevertheless, it must be noted that the clinical implications of finding 
a SNP that may affect the progress of a disease are limited as there are numerous other 
factors, including other SNPs, that affect the progression of all diseases. Hence, future 
studies should include the investigation of other SNPs and haplotypes. In recent years, 
studies of haplotype have become more common than those of single SNPs. Thus, the 
next logical step for the present study would be to examine haplotypes present in SOD2. 
This may help determine whether genetic variations affect the progression of CI(D. The 
apparent lack of association between SOD activity and SOD2 genotypes in the present 
study may be due to the fact that SOD2 is found in mitochondria, and is quite difficult 
to measure. Whilst there are methods to measure SOD activity in mitochondria in 
kidney cells, it was not possible to conduct this in the present study. It would be useful 
to investigate other SNPs, including those present in plasma GPx genes 177 , and to 
examine hap lotypes identified in antioxidant genes. Slowing the progression of CKD is 
a major priority for patients, nephrologists and the health fitnders. Therefore, when 
patients are identified as having a greater risk of progressing faster to ESRD, 
intervention is required. For example, a patient identified with the SOD2 Ala/Val or 
Val/Val genotype might be monitored more frequently to ensure that more timely (and 
intensive) treatment in an effort to slow the decline in kidney function. Presently, 
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treatment is based on blood pressure control by angiotensin converting enzyme 
inhibitors and angiotensin receptor blockers, and dietary and lifestyle changes. The 
present study provides some evidence for antioxidant intervention in the CICD 
population which suggests antioxidant supplementation may be beneficial. Hence, well 
designed randomised control trials involving antioxidant supplementation, with, 
GliSODin, a SOD supplementation that has been shown to up regulate antioxidants and 
protect against oxidative stress apoptosis, are warranted. 215 Finally, the current research 
suggests that CICD patients with specific SOD2 genotypes may progress to ESRD more 
rapidly compared to other patients. Therefore, with this knowledge, we may be able to 
help to slow the progression of CICD and delay dialysis whilst maintaining the quality 
of life of patients. This would undoubtedly reduce costs and allow for improved 
treatment of more people. 
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